<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:01:21Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4925012" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4925012</identifier><datestamp>2016-12-27</datestamp><setSpec>jexpmed</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Exp Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Exp. Med</journal-id>
      <journal-id journal-id-type="publisher-id">jem</journal-id>
      <journal-id journal-id-type="hwp">jem</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Experimental Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0022-1007</issn>
      <issn pub-type="epub">1540-9538</issn>
      <publisher>
        <publisher-name>The Rockefeller University Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4925012</article-id>
      <article-id pub-id-type="pmcid">PMC4925012</article-id>
      <article-id pub-id-type="pmc-uid">4925012</article-id>
      <article-id pub-id-type="pmid">27242165</article-id>
      <article-id pub-id-type="pmid">27242165</article-id>
      <article-id pub-id-type="publisher-id">20151110</article-id>
      <article-id pub-id-type="doi">10.1084/jem.20151110</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
          <subj-group>
            <subject>Article</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in <italic>LAT</italic></article-title>
        <alt-title alt-title-type="short">Human LAT deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Keller</surname>
            <given-names>Baerbel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="author-notes" rid="afn13">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zaidman</surname>
            <given-names>Irina</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
          <xref ref-type="author-notes" rid="afn13">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yousefi</surname>
            <given-names>O. Sascha</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
          <xref ref-type="aff" rid="aff4">4</xref>
          <xref ref-type="author-notes" rid="afn13">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hershkovitz</surname>
            <given-names>Dov</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stein</surname>
            <given-names>Jerry</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Unger</surname>
            <given-names>Susanne</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schachtrup</surname>
            <given-names>Kristina</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sigvardsson</surname>
            <given-names>Mikael</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kuperman</surname>
            <given-names>Amir A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">8</xref>
          <xref ref-type="aff" rid="aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shaag</surname>
            <given-names>Avraham</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schamel</surname>
            <given-names>Wolfgang W.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
          <xref ref-type="author-notes" rid="afn14">**</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Elpeleg</surname>
            <given-names>Orly</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">10</xref>
          <xref ref-type="author-notes" rid="afn14">**</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Warnatz</surname>
            <given-names>Klaus</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="author-notes" rid="afn14">**</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Stepensky</surname>
            <given-names>Polina</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">10</xref>
          <xref ref-type="aff" rid="aff11">11</xref>
          <xref ref-type="author-notes" rid="afn14">**</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution>Center for Chronic Immunodeficiency (CCI), University Medical Center and University of Freiburg, 79106 Freiburg, Germany</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution>Department of Pediatric Hematology Oncology, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa 3109601, Israel</institution>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution>Department of Molecular Immunology, Faculty of Biology, BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79104 Freiburg, Germany</institution>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <institution>Spemann Graduate School of Biology and Medicine (SGBM), Albert Ludwigs University Freiburg, 79104 Freiburg, Germany</institution>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <institution>Department of Pathology, Rambam Health Care Campus, Haifa 3109601, Israel</institution>
      </aff>
      <aff id="aff6">
        <label>6</label>
        <institution>Department of Pediatric Hematology Oncology and Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel, Petah-Tikva 49202, Israel</institution>
      </aff>
      <aff id="aff7">
        <label>7</label>
        <institution>Department of Clinical and Experimental Medicine, Experimental Hematopoiesis Unit, Faculty of Health Sciences, LinkÃ¶ping University, 581 85 LinkÃ¶ping, Sweden</institution>
      </aff>
      <aff id="aff8">
        <label>8</label>
        <institution>Blood Coagulation Service and Pediatric Hematology Clinic, Galilee Medical Center, Nahariya 22100, Israel</institution>
      </aff>
      <aff id="aff9">
        <label>9</label>
        <institution>Faculty of Medicine in the Galilee, Bar-Ilan University, Safed 5290002, Israel</institution>
      </aff>
      <aff id="aff10">
        <label>10</label>
        <institution>Monique and Jacques Roboh Department of Genetic Research, Hadassah Medical Center, Hebrew University, Jerusalem 91120, Israel</institution>
      </aff>
      <aff id="aff11">
        <label>11</label>
        <institution>Department of Pediatric Hematology-Oncology and Bone Marrow Transplantation, Hadassah Medical Center, Hebrew University, Jerusalem 91120, Israel</institution>
      </aff>
      <author-notes>
        <corresp id="cor12">Correspondence to Klaus Warnatz: <email>klaus.warnatz@uniklinik-freiburg.de</email>; or Polina Stepensky: <email>polina@hadassah.org.il</email></corresp>
        <fn id="afn13" fn-type="equal" specific-use="equal">
          <label>*</label>
          <p>B. Keller, I. Zaidman, and O.S. Yousefi contributed equally to this paper.</p>
        </fn>
        <fn id="afn14" fn-type="equal" specific-use="equal">
          <label>**</label>
          <p>W.W. Schamel, O. Elpeleg, K. Warnatz, and P. Stepensky contributed equally to this paper.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>27</day>
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <volume>213</volume>
      <issue>7</issue>
      <fpage>1185</fpage>
      <lpage>1199</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>7</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>5</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2016 Keller et al.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="openaccess">
          <license-p>This article is distributed under the terms of an AttributionâNoncommercialâShare AlikeâNo Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.rupress.org/terms">http://www.rupress.org/terms</ext-link>). After six months it is available under a Creative Commons License (AttributionâNoncommercialâShare Alike 3.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <self-uri xlink:role="icon" xlink:href="JEM_20151110_thumb.gif"/>
      <abstract abstract-type="precis">
        <p>Keller et al. describe for the first time human LAT deficiency, which causes severe immune dysregulation with autoimmunity, lymphoproliferation, and progressive immunodeficiency.</p>
      </abstract>
      <abstract>
        <p>The adapter protein linker for activation of T cells (LAT) is a critical signaling hub connecting T cell antigen receptor triggering to downstream T cell responses. In this study, we describe the first kindred with defective LAT signaling caused by a homozygous mutation in exon 5, leading to a premature stop codon deleting most of the cytoplasmic tail of LAT, including the critical tyrosine residues for signal propagation. The three patients presented from early childhood with combined immunodeficiency and severe autoimmune disease. Unlike in the mouse counterpart, reduced numbers of T cells were present in the patients. Despite the reported nonredundant role of LAT in Ca<sup>2+</sup> mobilization, residual T cells were able to induce Ca<sup>2+</sup> influx and nuclear factor (NF) ÎºB signaling, whereas extracellular signal-regulated kinase (ERK) signaling was completely abolished. This is the first report of a LAT-related disease in humans, manifesting by a progressive combined immune deficiency with severe autoimmune disease.</p>
      </abstract>
      <funding-group>
        <award-group id="sp1">
          <funding-source>
            <institution-wrap>
              <institution>Federal Ministry of Education and Research</institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/501100002347</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id rid="sp1">BMBF 01EO1303</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group id="sp2">
          <funding-source>
            <institution-wrap>
              <institution>Deutsche Forschungsgemeinschaft</institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/501100001659</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id rid="sp2">DFG WA 1597/4-1</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group id="sp3">
          <funding-source>
            <institution-wrap>
              <institution>German Research Foundation</institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/501100001659</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id rid="sp3">GSC-4</award-id>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <p>T cells are selected during thymic development based on the signal strength elicited through the interaction of the MHCâpeptide complex on APCs and the TCR on thymocytes. Although the specificity of the TCR plays a crucial role and allows for positive and negative selection, amplifying or dampening alterations of signaling proteins downstream of the TCR will modify signal strength and, consequently, impact the cellular response and outcome of selection. Multiple examples have illustrated the effect of altered TCR signal strength on the increased survival of autoreactive T cell clones in mice with genetic alterations of signaling molecules like ZAP70 (<xref rid="bib35" ref-type="bibr">Sakaguchi et al., 2003</xref>; <xref rid="bib38" ref-type="bibr">Siggs et al., 2007</xref>) or the CD3 signaling unit by deletion of several immunoreceptor tyrosine-based activating motives (<xref rid="bib15" ref-type="bibr">Holst et al., 2008</xref>). This signaling machinery downstream of the TCR is composed of a dynamic, fine-tuned network of multiple components that interact in a tightly regulated temporospatial manner. This is achieved by scaffold proteins, which allow the preassembly of signalosomes to facilitate rapid signal transduction and guarantee signal specificity. Although the lack of certain scaffold proteins like BLNK/SLP65 in B cells (<xref rid="bib26" ref-type="bibr">Minegishi et al., 1999</xref>) leads to the absence of affected lymphocyte subsets, the lack of others may allow for the development of the respective population but modify their activation or further differentiation.</p>
    <p>Linker for activation of T cells (LAT) is a transmembrane adapter molecule first discovered in activated T cells. LAT is phosphorylated after TCR triggering at four conserved tyrosine residues that are essential for the recruitment and membrane localization of downstream molecules: human (h)Y132/mouse (m)Y136, hY171/mY175, hY191/mY195, and hY226/mY235 (<xref rid="bib4" ref-type="bibr">Balagopalan et al., 2010</xref>). LAT knockout mice (<xref rid="bib49" ref-type="bibr">Zhang et al., 1999b</xref>) and mice with targeted replacement of all four tyrosine residues (<xref rid="bib40" ref-type="bibr">Sommers et al., 2001</xref>) lack peripheral T cells because of a block at the double-negative 3 stage. These tyrosines serve as docking sites for PLCÎ³1, Grb2, Gads, and others, interconnected in positive and negative regulatory plug-ins of (pre)assembled signaling modules (<xref rid="bib22" ref-type="bibr">Malissen et al., 2014</xref>; <xref rid="bib34" ref-type="bibr">Roncagalli et al., 2014</xref>) modifying T cell development (<xref rid="bib49" ref-type="bibr">Zhang et al., 1999b</xref>), specific functions (<xref rid="bib29" ref-type="bibr">Ou-Yang et al., 2012</xref>), or even terminating T cell activation (<xref rid="bib22" ref-type="bibr">Malissen et al., 2014</xref>). Mice with a mutation at Y136 of LAT, which is the docking site for PLCÎ³1, present with hypergammaglobulinemia and severe lupus-like glomerulonephritis and die within 6 wk (<xref rid="bib41" ref-type="bibr">Sommers et al., 2002</xref>), suggesting an essential role of this docking site for negative regulatory plug-ins. This deletion uncouples the activation of the CD28 pathway from the TCR by allowing for TCR-independent constitutive activation. Because of the distinctive pattern of this dysregulation in affected mice, it was termed LAT signaling pathology (<xref rid="bib33" ref-type="bibr">Roncagalli et al., 2010</xref>). In contrast to mice, the physiological role of LAT is not known in humans.</p>
    <p>Here, we describe for the first time the clinical course and immunological findings in a family with a homozygous loss-of-function mutation in LAT.</p>
    <sec sec-type="results" id="s01">
      <title>RESULTS</title>
      <sec id="s02">
        <title>Case studies</title>
        <p>We evaluated three siblings born to consanguineous parents of Arab origin (<xref ref-type="fig" rid="fig1">Fig. 1</xref>). All three patients presented with recurrent infection, lymphoproliferation, and life-threatening autoimmune disease since early infancy. The main clinical and laboratory findings are summarized in <xref ref-type="table" rid="tbl1">Table 1</xref>.</p>
        <fig id="fig1" fig-type="figure" orientation="portrait" position="float">
          <?Figure Small?>
          <label>Figure 1.</label>
          <caption>
            <p><bold>Pedigree of the affected family.</bold> Circles represent female and squares represent male subjects. Solid symbols show homozygous affected patients, and crossed-out symbols stand for deceased subjects. N, wild type. del, deletion.</p>
          </caption>
          <graphic xlink:href="JEM_20151110_Fig1"/>
        </fig>
        <table-wrap id="tbl1" orientation="portrait" position="float">
          <?Table Large?>
          <label>Table 1.</label>
          <caption>
            <title>Summary of major clinical and laboratory findings</title>
          </caption>
          <table frame="hsides" rules="groups">
            <col width="17%" span="1"/>
            <col width="28%" span="1"/>
            <col width="28%" span="1"/>
            <col width="27%" span="1"/>
            <thead>
              <tr>
                <th align="left" scope="col" rowspan="1" colspan="1"/>
                <th align="center" scope="col" rowspan="1" colspan="1">Patient 1, male</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Patient 2, male</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Patient 3, female</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Age at presentation</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">5 mo</td>
                <td align="center" rowspan="1" colspan="1">6 mo</td>
                <td align="center" rowspan="1" colspan="1">10 mo</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Infection</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Recurrent pneumonia, EBV/CMV viremia, CMV pneumonia</td>
                <td align="center" rowspan="1" colspan="1">Congenital toxoplasmosis, recurrent pneumonia, varicella infection, CMV viremia, Candida pneumonia adenovirus + CMV PCR positive in BAL</td>
                <td align="center" rowspan="1" colspan="1">Recurrent pneumonia, urinary infections, gastroenteritis, CMV viremia</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Autoimmunity</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Coombs<sup>+</sup> AIHA, ITP, autoimmune neutropenia</td>
                <td align="center" rowspan="1" colspan="1">Coombs<sup>+</sup> AIHA, ITP</td>
                <td align="center" rowspan="1" colspan="1">Anti-ADAMTS13<sup>+</sup> microangiopathic hemolytic anemia</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Lymphoproliferation</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Lymphadenopathy, splenomegaly</td>
                <td align="center" rowspan="1" colspan="1">Lymphadenopathy, splenomegaly</td>
                <td align="center" rowspan="1" colspan="1">Lymphadenopathy, splenomegaly</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Lung disease</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Chronic lung disease, bronchiectasis</td>
                <td align="center" rowspan="1" colspan="1">Chronic lung disease, bronchiectasis</td>
                <td align="center" rowspan="1" colspan="1">No</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Others</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Red-brown rash on face and legs</td>
                <td align="center" rowspan="1" colspan="1">Diplegic cerebral palsy due to congenital toxoplasmosis, red-brown rash on forearm</td>
                <td align="center" rowspan="1" colspan="1">No</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Treatment</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Steroids, IgG-RT, splenectomy</td>
                <td align="center" rowspan="1" colspan="1">Steroids, IgG-RT</td>
                <td align="center" rowspan="1" colspan="1">Steroids, plasmapheresis</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Outcome</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Died at 9 yr due to disseminated CMV infection</td>
                <td align="center" rowspan="1" colspan="1">Alive, 8 yr old, 13 mo after HSCT</td>
                <td align="center" rowspan="1" colspan="1">Died at 2 yr due to TTP</td>
              </tr>
              <tr>
                <td rowspan="8" align="left" scope="row" colspan="1">
                  <bold>Immunoglobulins</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Progressive hypogammaglobulinemia</td>
                <td align="center" rowspan="1" colspan="1">Progressive hypogammaglobulinemia</td>
                <td align="center" rowspan="1" colspan="1">Hypergammaglobulinemia</td>
              </tr>
              <tr>
                <td colspan="1" align="center" scope="row" rowspan="1">&lt;4 yr:</td>
                <td align="center" rowspan="1" colspan="1">&lt;3.5 yr:</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td colspan="1" align="center" scope="row" rowspan="1">normal</td>
                <td align="center" rowspan="1" colspan="1">normal to rather increased</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td colspan="1" align="center" scope="row" rowspan="1">4 yr:</td>
                <td align="center" rowspan="1" colspan="1">3.5 yr:</td>
                <td align="center" rowspan="1" colspan="1">2 yr:</td>
              </tr>
              <tr>
                <td colspan="1" align="center" scope="row" rowspan="1">IgG 1.6 g/liter (5.4â13.4 g/liter)</td>
                <td align="center" rowspan="1" colspan="1">IgG 1.3 g/liter (5.4â13.4 g/liter)</td>
                <td align="center" rowspan="1" colspan="1">IgG 20.45 g/liter (4.7â12.3 g/liter)</td>
              </tr>
              <tr>
                <td colspan="1" align="center" scope="row" rowspan="1">IgA &lt;0.16 g/liter (0.3â1.9 g/liter)</td>
                <td align="center" rowspan="1" colspan="1">IgA 0.69 g/liter (0.3â1.9 g/liter)</td>
                <td align="center" rowspan="1" colspan="1">IgA 1.02 g/liter (0.2â1.4 g/liter)</td>
              </tr>
              <tr>
                <td colspan="1" align="center" scope="row" rowspan="1">IgM 0.12 g/liter (0.4â1.7 g/liter)</td>
                <td align="center" rowspan="1" colspan="1">IgM 0.84 g/liter (0.4â1.7 g/liter)</td>
                <td align="center" rowspan="1" colspan="1">IgM 0.89 g/liter (0.4â1.5 g/liter)</td>
              </tr>
              <tr>
                <td colspan="1" align="center" scope="row" rowspan="1">IgE 2 IU/ml (&lt;58 IU/ml)</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">IgE 286 IU/ml (&lt;29 IU/ml)</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">8 yr:</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">IgG &lt;2 g/liter (6.5â15.3 g/liter)</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">IgA &lt;0.26 g/liter (0.5â2.5 g/liter)</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">IgM 0.39 g/liter (0.4â1.9 g/liter)</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Specific antibodies</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Hepatitis A<sup>+</sup>, HSV1<sup>+</sup>, Hepatitis B<sup>â</sup>, measles<sup>â</sup>, mumps<sup>â</sup>, rubella<sup>â</sup></td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="center" rowspan="1" colspan="1">rubella<sup>+</sup>, measles<sup>â</sup>, EBV<sup>+</sup>, CMV<sup>â</sup></td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Lymphocyte populations</bold>
                </td>
                <td align="center" rowspan="1" colspan="1">Progressive lymphopenia, high Î³Î´ T cells, low CD4 T cells</td>
                <td align="center" rowspan="1" colspan="1">Progressive lymphopenia, high Î³Î´ T cells, low CD4 T cells, low B cells</td>
                <td align="center" rowspan="1" colspan="1">High Î³Î´ T cells</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>AIHA, autoimmune hemolytic anemia; BAL, bronchoalveolar lavage; HSCT, hematopoietic stem cell transplantation; IgG-RT, Ig replacement therapy; ITP, idiopathic thrombocytopenic purpura; TTP, thrombotic thrombocytopenic purpura. Values in parentheses depict age-matched reference values.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>Patient 1 presented at the age of 5 mo with the first severe episode of Coombs-positive autoimmune hemolytic anemia and immune-mediated thrombocytopenia, lymphadenopathy, and massive splenomegaly. For progressive treatmentâresistant autoimmune cytopenia, he was splenectomized at the age of 7 yr, but at age 9, awaiting hematopoietic stem cell transplantation, he died because of disseminated CMV infection with pulmonary involvement. He had additionally suffered from chronic lung disease with bronchiectasis and disseminated purple edematous skin lesions on his face and arms.</p>
        <p>The index patient (patient 2) presented at the age of 7 mo with diplegic cerebral palsy and megalocystic leukencephalopathy probably caused by perinatal toxoplasmosis infection. From 1 yr of age, he suffered from recurrent respiratory tract infections, which progressed to chronic lung disease with bronchiectasis. Like his brother, he suffered from hepatosplenomegaly, lymphadenopathy, and persistent red edematous nodules on his forearms. From the age of 6 yr, he was treated with steroids for severe Evans syndrome. At age 7 yr, varicella infection was diagnosed, and shortly after, he developed CMV and adenoviral infection with severe progressive deterioration of respiratory function. On antiviral and IgG replacement therapy, he improved gradually, and genetic diagnosis was performed. Currently, at the age of 8 yr, he successfully received an allogeneic stem cell transplantation from his fully matched heterozygous sibling.</p>
        <p>The younger sister (patient 3) presented at the age of 10 mo with gastroenteritis, recurrent pneumonia, and urinary tract infection. At the age of 2 yr, she died of anti-ADAMTS13âpositive microangiopathic hemolytic anemia and thrombocytopenia.</p>
        <p>The histological examination of lymph nodes from patients 1 and 2 showed distorted architecture with poorly formed follicles (not depicted). Aggregates of small, CD20-positive cells were associated with CD21-positive follicular dendritic cells, but Bcl6-positive germinal centers were absent. The spleen of patient 1 resembled the findings in the lymph nodes (not depicted). The skin biopsies showed extensive lymphoid infiltration of the dermis but not the epidermis, mainly by CD8 T cells. In situ hybridization for EBV-encoded RNA in the skin was negative as well as histochemical stains for fungi and acid-fast bacteria (not depicted).</p>
      </sec>
      <sec id="s03">
        <title>Immune phenotype of LAT-mutated patients</title>
        <p>Patient 1 presented with initially normal T, B, and NK cell counts, mitogen responses (Con A and pokeweed mitogen), and serum Ig levels. At the age of 4 yr, he developed hypogammaglobulinemia with partially reduced specific antibody responses. An increased number of Î³Î´ T cells (up to 80% of T cells) was noted on several occasions. At 6 yr of age, decreased CD4 T cells and B cells and increased CD4-negative/CD8-negative T cells, presumably representing the already beforehand increased Î³Î´ T cells (<xref ref-type="table" rid="tbl2">Table 2</xref>), were noted.</p>
        <table-wrap id="tbl2" orientation="portrait" position="float">
          <?Table Large?>
          <label>Table 2.</label>
          <caption>
            <title>Immune phenotype of patient 1, 2, and 3</title>
          </caption>
          <table frame="hsides" rules="groups">
            <col width="13%" span="1"/>
            <col width="7%" span="1"/>
            <col width="8%" span="1"/>
            <col width="7%" span="1"/>
            <col width="8%" span="1"/>
            <col width="3%" span="1"/>
            <col width="6%" span="1"/>
            <col width="7%" span="1"/>
            <col width="6%" span="1"/>
            <col width="7%" span="1"/>
            <col width="2%" span="1"/>
            <col width="6%" span="1"/>
            <col width="7%" span="1"/>
            <col width="6%" span="1"/>
            <col width="7%" span="1"/>
            <thead>
              <tr>
                <th rowspan="2" align="left" scope="col" colspan="1"/>
                <th colspan="4" align="center" scope="colgroup" rowspan="1">Patient 1 (6 yr)</th>
                <th rowspan="2" align="left" scope="col" colspan="1"/>
                <th colspan="4" align="center" scope="colgroup" rowspan="1">Patient 2 (8 yr)</th>
                <th rowspan="2" align="left" scope="col" colspan="1"/>
                <th colspan="4" align="center" scope="colgroup" rowspan="1">Patient 3 (2 yr)</th>
              </tr>
              <tr>
                <th colspan="1" align="center" scope="colgroup" rowspan="1">Relative counts</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Reference values</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Absolute</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Reference values</th>
                <th colspan="1" align="center" scope="colgroup" rowspan="1">Relative counts</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Reference values</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Absolute</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Reference values</th>
                <th colspan="1" align="center" scope="colgroup" rowspan="1">Relative counts</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Reference values</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Absolute</th>
                <th align="center" scope="col" rowspan="1" colspan="1">Reference values</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Lymphocytes</bold>
                  <xref ref-type="table-fn" rid="ttbl2n2">
                    <sup>a</sup>
                  </xref>
                </td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">1,855</td>
                <td align="center" rowspan="1" colspan="1">1,800â5,000</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">900</td>
                <td align="center" rowspan="1" colspan="1">1,800â5,000</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">4,950</td>
                <td align="center" rowspan="1" colspan="1">2,800â6,400</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>B cells</bold>
                  <xref ref-type="table-fn" rid="ttbl2n2">
                    <sup>a</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">2.0</td>
                <td align="center" rowspan="1" colspan="1">8.5â20.2</td>
                <td align="center" rowspan="1" colspan="1">37</td>
                <td align="center" rowspan="1" colspan="1">296â784</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">3.8</td>
                <td align="center" rowspan="1" colspan="1">8.5â20.2</td>
                <td align="center" rowspan="1" colspan="1">34</td>
                <td align="center" rowspan="1" colspan="1">296â784</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">29.9</td>
                <td align="center" rowspan="1" colspan="1">17.3â30.0</td>
                <td align="center" rowspan="1" colspan="1">1,480</td>
                <td align="center" rowspan="1" colspan="1">686â1,732</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>CD4</bold>
                  <xref ref-type="table-fn" rid="ttbl2n2">
                    <sup>a</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">4.0</td>
                <td align="center" rowspan="1" colspan="1">26.5â41.4</td>
                <td align="center" rowspan="1" colspan="1">74</td>
                <td align="center" rowspan="1" colspan="1">641â1,453</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">24.5</td>
                <td align="center" rowspan="1" colspan="1">26.5â41.4</td>
                <td align="center" rowspan="1" colspan="1">220</td>
                <td align="center" rowspan="1" colspan="1">641â1,453</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">6.4</td>
                <td align="center" rowspan="1" colspan="1">28.1â43.2</td>
                <td align="center" rowspan="1" colspan="1">317</td>
                <td align="center" rowspan="1" colspan="1">925â2,477</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>CD8</bold>
                  <xref ref-type="table-fn" rid="ttbl2n3">
                    <sup>b</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">45.0</td>
                <td align="center" rowspan="1" colspan="1">13â47</td>
                <td align="center" rowspan="1" colspan="1">834</td>
                <td align="center" rowspan="1" colspan="1">200â1,700</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">38.3</td>
                <td align="center" rowspan="1" colspan="1">13â47</td>
                <td align="center" rowspan="1" colspan="1">345</td>
                <td align="center" rowspan="1" colspan="1">200â1,700</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">4.5</td>
                <td align="center" rowspan="1" colspan="1">9â49</td>
                <td align="center" rowspan="1" colspan="1">223</td>
                <td align="center" rowspan="1" colspan="1">200â1,800</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>NK cells</bold>
                  <xref ref-type="table-fn" rid="ttbl2n3">
                    <sup>b</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">6.0</td>
                <td align="center" rowspan="1" colspan="1">2â31</td>
                <td align="center" rowspan="1" colspan="1">114</td>
                <td align="center" rowspan="1" colspan="1">70â590</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">1.7</td>
                <td align="center" rowspan="1" colspan="1">2â31</td>
                <td align="center" rowspan="1" colspan="1">16</td>
                <td align="center" rowspan="1" colspan="1">70â590</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">0.9</td>
                <td align="center" rowspan="1" colspan="1">2â25</td>
                <td align="center" rowspan="1" colspan="1">45</td>
                <td align="center" rowspan="1" colspan="1">61â510</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>B cell subpopulations</bold>
                  <xref ref-type="table-fn" rid="ttbl2n2">
                    <sup>a</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Transitional</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">21.1</td>
                <td align="center" rowspan="1" colspan="1">3.4â9.0</td>
                <td align="center" rowspan="1" colspan="1">5</td>
                <td align="center" rowspan="1" colspan="1">13â63</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Naive</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">68.7</td>
                <td align="center" rowspan="1" colspan="1">47.8â69.8</td>
                <td align="center" rowspan="1" colspan="1">23</td>
                <td align="center" rowspan="1" colspan="1">154â413</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">IgM memory</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">3.5</td>
                <td align="center" rowspan="1" colspan="1">6.3â22</td>
                <td align="center" rowspan="1" colspan="1">2</td>
                <td align="center" rowspan="1" colspan="1">24â135</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">IgM only</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">0.7</td>
                <td align="center" rowspan="1" colspan="1">2â11.8</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">7â65</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">IgA cs memory</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">0</td>
                <td align="center" rowspan="1" colspan="1">1.1â6.1</td>
                <td align="center" rowspan="1" colspan="1">0</td>
                <td align="center" rowspan="1" colspan="1">5â35</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">IgG cs memory</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">0</td>
                <td align="center" rowspan="1" colspan="1">2.7â14</td>
                <td align="center" rowspan="1" colspan="1">0</td>
                <td align="center" rowspan="1" colspan="1">13â74</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">CD21<sup>low</sup></td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">6.3</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>CD4 subpopulations</bold>
                  <xref ref-type="table-fn" rid="ttbl2n2">
                    <sup>a</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">RTE<xref ref-type="table-fn" rid="ttbl2n4"><sup>c</sup></xref></td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">24.4</td>
                <td align="center" rowspan="1" colspan="1">61â84.2</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Naive</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">2.4</td>
                <td align="center" rowspan="1" colspan="1">55.6â75.8</td>
                <td align="center" rowspan="1" colspan="1">5</td>
                <td align="center" rowspan="1" colspan="1">375â1,096</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">CD45R0</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">97.5</td>
                <td align="center" rowspan="1" colspan="1">24â43</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">T reg cells</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">2.0</td>
                <td align="center" rowspan="1" colspan="1">2.3â7.7</td>
                <td align="center" rowspan="1" colspan="1">5</td>
                <td align="center" rowspan="1" colspan="1">18â86</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">cTFH<xref ref-type="table-fn" rid="ttbl2n5"><sup>d</sup></xref></td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">35.0</td>
                <td align="center" rowspan="1" colspan="1">18.4â29.9</td>
                <td align="center" rowspan="1" colspan="1">112</td>
                <td align="center" rowspan="1" colspan="1">51â218</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Th<sub>2</sub><sup>+</sup>Th<sub>17</sub>-like cTFH<xref ref-type="table-fn" rid="ttbl2n5"><sup>d</sup></xref></td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">29.4</td>
                <td align="center" rowspan="1" colspan="1">39.9â66.1</td>
                <td align="center" rowspan="1" colspan="1">33</td>
                <td align="center" rowspan="1" colspan="1">26â85</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>CD8 subpopulations</bold>
                  <xref ref-type="table-fn" rid="ttbl2n3">
                    <sup>b</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Naive</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">0.3</td>
                <td align="center" rowspan="1" colspan="1">16â100</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">42â1,300</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Central memory</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">2.4</td>
                <td align="center" rowspan="1" colspan="1">1â6</td>
                <td align="center" rowspan="1" colspan="1">8</td>
                <td align="center" rowspan="1" colspan="1">6â43</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Effector memory</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">65.9</td>
                <td align="center" rowspan="1" colspan="1">5â100</td>
                <td align="center" rowspan="1" colspan="1">227</td>
                <td align="center" rowspan="1" colspan="1">45â410</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">Terminally differentiated</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">1.6</td>
                <td align="center" rowspan="1" colspan="1">15â41</td>
                <td align="center" rowspan="1" colspan="1">6</td>
                <td align="center" rowspan="1" colspan="1">57â340</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Î³Î´ T cells</bold>
                  <xref ref-type="table-fn" rid="ttbl2n6">
                    <sup>e</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">37.2</td>
                <td align="center" rowspan="1" colspan="1">&lt;10</td>
                <td align="center" rowspan="1" colspan="1">282</td>
                <td align="center" rowspan="1" colspan="1">12â175</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">72</td>
                <td align="center" rowspan="1" colspan="1">&lt;10</td>
                <td align="center" rowspan="1" colspan="1">2,217</td>
                <td align="center" rowspan="1" colspan="1">12â175</td>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>DN T cells</bold>
                  <xref ref-type="table-fn" rid="ttbl2n6">
                    <sup>e</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">51</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">38</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">72</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td align="left" scope="row" rowspan="1" colspan="1">
                  <bold>NK T cells</bold>
                  <xref ref-type="table-fn" rid="ttbl2n6">
                    <sup>e</sup>
                  </xref>
                </td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="char" char="." rowspan="1" colspan="1">0.005</td>
                <td align="center" rowspan="1" colspan="1">&gt;0.01</td>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
                <td align="center" rowspan="1" colspan="1">ND</td>
                <td align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>Relative counts are shown as a percentage of parental population. Absolute numbers refer to cells/microliter. CD4 T cell subpopulations: recent thymic emigrants (RTEs), CD31<sup>+</sup> of CD45RA<sup>+</sup> CD4 T cells; T reg cells, CD127<sup>â</sup> CD25hi of CD45RA<sup>â</sup> CD4 T cells; circulating T follicular helperâlike cell (cTFH), CXCR5<sup>+</sup> of CD45RA<sup>â</sup> CD4 T cells; Th2/Th17-like cTFH, CXCR3<sup>â</sup> of CXCR5<sup>+</sup> CD45RA<sup>â</sup> CD4 T cells. CD8 T cell populations: naive, CCR7<sup>+</sup> CD45RA<sup>+</sup> CD27<sup>+</sup>; terminally differentiated, CCR7<sup>â</sup> CD45RA<sup>+</sup> CD27<sup>â</sup>; central memory, CCR7<sup>+</sup> CD45RA<sup>â</sup> CD27<sup>+</sup>; effector memory, CCR7<sup>â</sup> CD45RA<sup>â</sup> CD27<sup>â</sup>. Double-negative (DN) T cells, CD4<sup>â</sup>/CD8<sup>â</sup> of CD3 T cells. NK T cells, VÎ±24 VÎ²11 CD3 T cells. cs, class switched.</p>
            <fn specific-use="standard" id="ttbl2n2">
              <label>a</label>
              <p><xref rid="bib45" ref-type="bibr">van Gent et al., 2009</xref>. </p>
            </fn>
            <fn specific-use="standard" id="ttbl2n3">
              <label>b</label>
              <p><xref rid="bib36" ref-type="bibr">SchatorjÃ© et al., 2012</xref>. </p>
            </fn>
            <fn specific-use="standard" id="ttbl2n4">
              <label>c</label>
              <p>Percentage of naive CD4 T cells. </p>
            </fn>
            <fn specific-use="standard" id="ttbl2n5">
              <label>d</label>
              <p>Internal reference value. </p>
            </fn>
            <fn specific-use="standard" id="ttbl2n6">
              <label>e</label>
              <p>Internal reference value of CD3 T cells.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Patient 2 showed repeatedly normal numbers of T, B, and NK cells. Ig levels dropped from hypergammaglobulinemia with normal IgA and IgM to panhypogammaglobulinemia. At the age of 8, IgG replacement therapy was started. T, B, and NK cells gradually decreased from the age of 6 yr with persistently increased numbers of Î³Î´ T cells. At the age of 8 yr, patient 2 had developed panlymphopenia leading to strongly reduced absolute counts of all B and CD4 T cell subpopulations. CD4 T cells were severely decreased, especially affecting the naive CD4 T cell subpopulation, whereas the percentage of regulatory T cells and circulating T follicular helper cell populations showed minor changes (<xref ref-type="table" rid="tbl2">Table 2</xref>). Comparing the distribution of CCR7, CD27, and CD28 (<xref rid="bib28" ref-type="bibr">Okada et al., 2008</xref>) in CD45R0 CD4 T cells of the patient with five healthy controls, we observed a relative increase of (CCR7<sup>â</sup>/CD27<sup>+</sup>/CD28<sup>+</sup>) effector memory T cells (33.4%; mean Â± standard deviation, 23.2 Â± 7.4%), reduced (CCR7<sup>+</sup>/CD27<sup>+</sup>/CD28<sup>+</sup>) central memory T cells (3.5%; 13.3 Â± 4.9%), and a relative increase of (CCR7<sup>â</sup>/CD27<sup>â</sup>/CD28<sup>+/â</sup>) effector T cells (42.6%; 8.1 Â± 6.5%), which is even more remarkable given the young age of the patient. Among CD8 T cells, naive and terminally differentiated CD8 T cells were diminished, but central and effector memory CD8 T cells were normal. Absolute and relative numbers of B cells were reduced, and a relative increase of transitional B cells was observed, whereas class-switched and IgM memory B cells were strongly decreased. Given the initial records of normal numbers of B and NK cells in patient 2 and normal Ig levels in all siblings at a younger age, the latter changes are likely to be secondary to progressive immune dysregulation.</p>
        <p>The immunological evaluation of patient 3 at the age of 2 yr was remarkable for hypergammaglobulinemia and elevated IgE. She had reduced NK cells but normal numbers of B cells and total T cells. The T cell compartment showed reduced relative and absolute CD4 T cells and reduced percentages of CD8 T cells but, like her siblings, strongly increased Î³Î´ T cells (<xref ref-type="table" rid="tbl2">Table 2</xref>).</p>
        <p>In the heterozygous parents, all lymphocyte subset counts and Ig levels were within the normal range, whereas the heterozygous sister had nearly 10% Î³Î´ T cells and slightly increased levels of all Ig isotypes (unpublished data).</p>
      </sec>
      <sec id="s04">
        <title>Molecular characterization of the LAT mutation</title>
        <p>The exome analysis of patient 2 yielded 54.1 million confidently mapped reads with a mean coverage of Ã62. After alignment to the reference genome (Hg19) and variant calling, we removed variants that were called less than Ã8, were off target, synonymous, heterozygous, predicted benign by Mutation Taster software, with minor allele frequencies &gt;0.1% in the dbSNP138 or minor allele frequencies &gt;1% in the Hadassah in-house database. 12 homozygous variants remained, but only chr16:28997725 deletion (del) GG (RefSeq accession no. <ext-link ext-link-type="NCBI:refseq" xlink:href="NM_001014987">NM_001014987</ext-link><ext-link ext-link-type="NCBI:refseq" xlink:href=".1">.1</ext-link>: c.268_269del) segregated with the disease in the family. The mutation was not present in any of the nearly 60,000 exomes deposited by the Exome Aggregation Consortium. This mutation caused a deletion of guanosines 268/269 in exon 5 of <italic>LAT</italic>, leading to a frame shift and a premature stop codon after 303 bp (<xref ref-type="fig" rid="fig2">Fig. 2 A</xref>). The predicted protein of 100 of the 233 aa contains an intact extracellular and transmembrane region but a shortened intracellular region, eliminating the known major phosphorylation sites Y132, Y171, Y191, and Y226 (<xref ref-type="fig" rid="fig2">Fig. 2 B</xref>). We did not identify any additional pathogenic mutations by whole exome sequencing.</p>
        <fig id="fig2" fig-type="figure" orientation="portrait" position="float">
          <?Figure Med?>
          <label>Figure 2.</label>
          <caption>
            <p><bold>Molecular characterization of LAT mutation.</bold> (A) Genomic DNA sequence around the c.268_269delGG mutation site (arrows) of a patient (top), a parent (middle), and an unrelated healthy control (ctrl; bottom). (B) Schematic view of wild-type LAT showing the extracellular region (ER), the transmembrane domain (TM), and the intracellular region (IR) with the four tyrosine residues phosphorylated downstream of TCR signaling. Below is the mutated form of the protein. The presumptive position of the frame shift starting at 89 aa and the presumed truncation after 100 aa is shown in red. (C) Relative mRNA expression of LAT with hypoxanthine phosphoribosyltransferase as the housekeeping gene is shown in CD4 CD45R0 T cells of patient 2 and three controls normalized to Jurkat cells. (D) FACS plot for LAT expression gated on CD4 CD45R0 T cells and graph of the mean fluorescence intensity (MFI) of LAT in CD4 and CD8 T cells in patient 2, the heterozygous sister, and three healthy controls. (E) Anti-FLAG staining and ZsGreen1 expression are shown in J.CaM2.5 cells expressing the recombinant wild-type (LAT<sup>wt</sup>) or the mutated LAT protein (LAT<sup>mut</sup>). (F) Immunodetection of FLAG-tagged LAT<sup>wt</sup> or LAT<sup>mut</sup> in J.CaM2.5 cells. The immunoblot is representative of three independent experiments.</p>
          </caption>
          <graphic xlink:href="JEM_20151110_Fig2"/>
        </fig>
        <p>The relative amount of <italic>LAT</italic> mRNA in patientâs sorted CD4 CD45R0 T cells was within the range of three different healthy controls (<xref ref-type="fig" rid="fig2">Fig. 2 C</xref>), indicating that the mutation does not interfere with transcript stability. The LAT protein, however, could not be detected by flow cytometry using an antibody directed against the intracytoplasmic part of LAT in CD4 T cells (<xref ref-type="fig" rid="fig2">Fig. 2 D</xref>) and by Western blotting of patient-derived EBV lines using a polyclonal antibody against LAT (not depicted). Interestingly, LAT staining in the heterozygous sibling showed normal levels of LAT in the majority of cells but a small percentage of cells with low to absent protein expression (<xref ref-type="fig" rid="fig2">Fig. 2 D</xref>). To test whether the putative truncated protein can be expressed, LAT-deficient Jurkat-derived J.CaM2.5 cells (<xref rid="bib11" ref-type="bibr">Finco et al., 1998</xref>) were stably transduced with the mutated form of the protein (J.CaM2.5-LAT<sup>mut</sup>) or with wild-type LAT (J.CaM2.5-LAT<sup>wt</sup>). Both were tagged with a FLAG sequence and cotransfected with ZsGreen1 separated by an internal ribosomal entry site. FLAG expression correlated with ZsGreen1 expression, indicating that translation efficiency of the FLAG-tagged LAT and the ZsGreen1 sequence is identical (<xref ref-type="fig" rid="fig2">Fig. 2 E</xref>). Western blotting with anti-FLAG tag but not the polyclonal anti-LAT antibody (not depicted) detected a shortened LAT<sup>mut</sup> protein in the transduced J.CaM2.5-LAT<sup>mut</sup> cells compared with J.CaM2.5-LAT<sup>wt</sup> cells (<xref ref-type="fig" rid="fig2">Fig. 2 F</xref>), indicating that the mutated LAT protein can be expressed. The loss of dominant immunogenic epitopes in the truncated LAT might explain the absent recognition by the polyclonal antibody targeting full-length LAT.</p>
      </sec>
      <sec id="s05">
        <title>Signaling capacity of mutant LAT in Jurkat cells</title>
        <p>The TCR-induced LAT signaling capacity was analyzed in J.CaM2.5-LAT<sup>wt</sup> or J.CaM2.5-LAT<sup>mut</sup> cells. After CD3 cross-linking, similar TCR-proximal ZAP70 phosphorylation was observed in LAT-deficient, LAT<sup>wt</sup>-, and LAT<sup>mut</sup>-expressing T cell lines (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). In line with the literature that PLCÎ³1 phosphorylation depends on the assembly of the LAT-SLP76 signalosome (<xref rid="bib39" ref-type="bibr">Smith-Garvin et al., 2009</xref>), PLCÎ³1 phosphorylation was absent in J.CaM2.5 and J.CaM2.5-LAT<sup>mut</sup> cells (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). Interestingly, the phosphorylation of IL-2âinducible T cell kinase (ITK), also reported to be dependent on LAT (<xref rid="bib37" ref-type="bibr">Shan and Wange, 1999</xref>), was not affected by the absence of LAT or the presence of LAT<sup>mut</sup> (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>). TCR-induced Ca<sup>2+</sup> mobilization was restored by LAT<sup>wt</sup> expression but absent in J.CaM2.5 and J.CaM2.5-LAT<sup>mut</sup> cells (<xref ref-type="fig" rid="fig3">Fig. 3 C</xref>), indicating that the truncated protein itself is not capable of mediating TCR-induced inositol 1,4,5-trisphosphate (IP<sub>3</sub>) production and subsequent Ca<sup>2+</sup> flux. Similarly, extracellular signal-regulated kinase (ERK) phosphorylation and up-regulation of CD69 was strongly reduced in J.CaM2.5-LAT<sup>mut</sup> and J.CaM2.5 cells compared with J.CaM2.5-LAT<sup>wt</sup> cells (<xref ref-type="fig" rid="fig3">Fig. 3 D</xref>), showing that the mutation interferes with LAT signaling.</p>
        <fig id="fig3" fig-type="figure" orientation="portrait" position="float">
          <?Figure Med?>
          <label>Figure 3.</label>
          <caption>
            <p><bold>TCR-induced signaling in LAT<sup>mut</sup> T cells.</bold> (AâD) All experiments were performed in LAT-deficient J.CaM2.5 cells and J.CaM2.5 cells reconstituted with LAT<sup>wt</sup> or LAT<sup>mut</sup>. (A) Immunoblot of ZAP70 and PLCÎ³1 phosphorylation with or without stimulation with 5 Âµg/ml anti-CD3 for 3 min. (B) Phosphorylation of ITK (pITK) with or without stimulation with 5 Âµg/ml anti-CD3 for 2 min. (C) Ca<sup>2+</sup> mobilization after anti-CD3 stimulation. (D) Phosphorylation of ERK (pERK) after 2-min anti-CD3 stimulation and up-regulation of CD69 after overnight stimulation. All results are representative of three to five independent experiments.</p>
          </caption>
          <graphic xlink:href="JEM_20151110_Fig3"/>
        </fig>
      </sec>
      <sec id="s06">
        <title>Signaling in LAT<sup>mut</sup> lymphocytes</title>
        <p>Next, we addressed the effect of the mutated LAT on TCR signaling in primary T cells of patient 2 after stimulation with anti-CD3 or anti-CD3/anti-CD28. As previously reported in LAT-deficient mice (<xref rid="bib3" ref-type="bibr">Archambaud et al., 2009</xref>), we observed significantly decreased CD3 expression on LAT<sup>mut</sup> CD4 T cells (<xref ref-type="fig" rid="fig4">Fig. 4 A</xref>), in contrast to mice not on CD8 T cells.</p>
        <fig id="fig4" fig-type="figure" orientation="portrait" position="float">
          <?Figure Small?>
          <label>Figure 4.</label>
          <caption>
            <p><bold>TCR signaling in primary LAT-mutated T cells.</bold> (A) Expression of CD3 on CD4 (left) and CD8 T cells (right) in three different experiments compared with controls. Patient 2 is shown in red, and controls are in blue. MFI, mean fluorescence intensity. ns, not significant. ***, P â¤ 0.001. (B and C) Phosphorylation of ITK (pITK; B) and ERK (pERK; C) in patientâs and controlsâ CD45R0 and CD45RA CD4 T cells without (closed) and after CD3 stimulation (open). Results are representative of five and four independent experiments. (D) Ca<sup>2+</sup> mobilization after cross-linking of CD3 is depicted in CD45R0 CD4 T cells and CD45R0 CD8 T cells of two controls and the LAT-mutated patient 2. Arrows indicate the addition of goat anti-mouse for CD3 cross-linking and ionomycin. The graph shows the relative Ca<sup>2+</sup> influx determined by the peak of Indo-1 bound/unbound normalized to the highest day control in three independent experiments. (E) Degradation of IÎºBÎ± is shown in CD45R0 CD4 T cells of patient 2 and a healthy control after stimulation with anti-CD3/anti-CD28. Results are representative of two independent experiments. ctrl, control. unst, unstimulated.</p>
          </caption>
          <graphic xlink:href="JEM_20151110_Fig4"/>
        </fig>
        <p>In line with reconstituted J.CaM2.5 cells, phosphorylation of ITK was observed in CD45R0 CD4 T cells of patient 2 after CD3 cross-linking (<xref ref-type="fig" rid="fig4">Fig. 4 B</xref>), and the phosphorylation of ERK was absent in LAT<sup>mut</sup>-expressing CD4 T cell subpopulations (<xref ref-type="fig" rid="fig4">Fig. 4 C</xref>). Surprisingly, and in contrast to our reconstitution experiments and to mouse LAT-deficient T cells, Ca<sup>2+</sup> mobilization was detectable in three independent experiments in CD45R0 CD4 T cells and CD45R0 CD8 T cells of the patient and was predominantly within the range of healthy controls (<xref ref-type="fig" rid="fig4">Fig. 4 D</xref>). Ca<sup>2+</sup> mobilization in naive CD4 was not evaluable because of extremely low cell counts. In line with the preserved Ca<sup>2+</sup> response, IÎºBÎ± degradation, which is also downstream of PLCÎ³1 activation, occurred normally after CD3/CD28 co-stimulation (<xref ref-type="fig" rid="fig4">Fig. 4 E</xref>), indicating that signaling was partially maintained in primary T cells in the absence of LAT. Genomic DNA sequencing of isolated CD45R0 CD4 T cells was performed to exclude reversion of the mutation as a potential explanation for this finding. However, only mutated <italic>LAT</italic> was detected in this population (not depicted). In addition, the possibility of alternative splicing was addressed by testing the mutant sequence for potential new splice sites. Two possible variants were predicted in silico. However, both variants were not detectable by PCR. Furthermore, RNA sequencing data of sorted CD45R0 CD4, CD8, and Î³Î´ T cells showed various fragments covering the genomically encoded 2-bp deletion, but no fragments compatible with the predicted aberrant splicing variants were detected (unpublished data). In T cells of the heterozygous parents and sister, the phosphorylation of ZAP70, ITK, ERK, and Ca<sup>2+</sup> mobilization was found to be normal (not depicted), indicating that there is no dominant-negative effect of the mutation in the heterozygous situation.</p>
      </sec>
      <sec id="s07">
        <title>Expression of alternative adapter molecules in LAT<sup>mut</sup> T cells</title>
        <p>Given the preserved Ca<sup>2+</sup> response in primary T cells in contrast to J.CaM2.5-LAT<sup>mut</sup> cells, we searched for adapter molecules potentially replacing the function of LAT with regard to Ca<sup>2+</sup> mobilization. Expression of the adapter molecules SIT, TRIM (TCR-interacting molecule), LAX (linker for activation of X cells), LIME, and PAG did not remarkably differ in patientsâ T cells compared with two controls in RNA sequencing analysis (<xref ref-type="fig" rid="fig5">Fig. 5 A</xref>). Because RNA for nonâT cell activation linker (NTAL)/linker for activation of B cells (LAB), the B cell homologue of LAT, was increased, we investigated protein expression in primary T cells but could not detect protein expression (<xref ref-type="fig" rid="fig5">Fig. 5 B</xref>).</p>
        <fig id="fig5" fig-type="figure" orientation="portrait" position="float">
          <?Figure Small?>
          <label>Figure 5.</label>
          <caption>
            <p><bold>Analysis of alternative adapter molecules in LAT-mutated T cells.</bold> (A) Volcano plot displaying the p-value versus log2 fold change in gene expression of selected adapter molecules in CD4 CD45R0 T cells of patient 2 compared with the mean expression value (base mean) of two controls determined by RNA sequencing. (B) Expression of LAB/NTAL in patient 2, the heterozygous sibling, and three controls. (C) CD6 expression in primary T cells of patient 2 and a healthy control (ctrl) and in LAT-transduced or nontransduced J.CaM2.5 cell lines (representative of two and four independent experiments, respectively). (D) CD6 and ZsGreen1 expression after transduction of a CD6 expression vector in J.CaM2.5, J.CaM2.5-LAT<sup>wt</sup>, and J.CaM2.5-LAT<sup>mut</sup> cells (top). Ca<sup>2+</sup> mobilization in CD6-negative (CD6<sup>neg</sup>) versus CD6-positive (CD6<sup>pos</sup>) J.CaM2.5, J.CaM2.5-LAT<sup>wt</sup>, and J.CaM2.5-LAT<sup>mut</sup> cells after anti-CD3 stimulation (bottom). The results are representative of four independent experiments. iono, ionomycin.</p>
          </caption>
          <graphic xlink:href="JEM_20151110_Fig5"/>
        </fig>
        <p>CD6 was expressed on primary T cells of the patient and controls, whereas it was nearly absent on J.CaM2.5 cells (<xref ref-type="fig" rid="fig5">Fig. 5 C</xref>). To investigate the influence of CD6 on Ca<sup>2+</sup> induction in the absence of LAT, J.CaM2.5, J.CaM2.5-LAT<sup>wt</sup>, and J.CaM2.5-LAT<sup>mut</sup> cells were stably transduced with CD6. Ca<sup>2+</sup> mobilization was determined in nonselected CD6-transduced cell lines after gating on CD6-positive or CD6-negative cells. We could not observe an improvement of Ca<sup>2+</sup> mobilization in CD6-expressing J.CaM2.5 and J.CaM2.5-LAT<sup>mut</sup> cells, implying that CD6 could not compensate for LAT deficiency in these T cell lines (<xref ref-type="fig" rid="fig5">Fig. 5 D</xref>). Thus, CD6 expression in Jurkat-derived cell lines is not sufficient to replace LAT function.</p>
      </sec>
      <sec id="s08">
        <title>Lymphocyte activation and function</title>
        <p>The primary T cells of patient 2 were analyzed for functional impairment caused by the <italic>LAT</italic> mutation. In accordance with LAT-deficient mice, a high percentage of LAT<sup>mut</sup>-expressing CD4 T cells constitutively produced IL-4, implying an expansion of the T helper type 2 cell (Th2) phenotype (<xref ref-type="fig" rid="fig6">Fig. 6 A</xref>). In addition, the percentage of IFN-Î³âproducing CD4 T cells was slightly increased after PMA/ionomycin stimulation. The percentage of IL-17 and IL-2 producing CD45R0 CD4 T cells was similar to the controls after in vitro stimulation with PMA/ionomycin (<xref ref-type="fig" rid="fig6">Fig. 6 A</xref>). Anti-CD3 stimulation for 20 h induced only reduced levels of CD69, inducible T cell co-stimulator (ICOS), and CD25 in LAT<sup>mut</sup> T cells, which could not be increased by the addition of anti-CD28 (<xref ref-type="fig" rid="fig6">Fig. 6 B</xref>). Similarly, in vitro proliferation of CD4 T cells (<xref ref-type="fig" rid="fig6">Fig. 6 C</xref>) and CD8 T cells (not depicted) after stimulation with anti-CD3, anti-CD3/anti-CD28 was abrogated and strongly reduced after PHA compared with the control. Finally, the degranulation of LAT<sup>mut</sup> CTLs after stimulation with anti-CD3/anti-CD28 beads (<xref ref-type="fig" rid="fig6">Fig. 6 D</xref>) and of patient-derived NK cells after stimulation with the K562 cell line was reduced (<xref ref-type="fig" rid="fig6">Fig. 6 E</xref>), although not absent. Accordingly, NK cells of patient 1 showed diminished cytotoxicity compared with day controls (not depicted). This might reflect previous results from mice that signaling via LAT is not essential but beneficial for the process of degranulation (<xref rid="bib29" ref-type="bibr">Ou-Yang et al., 2012</xref>; <xref rid="bib25" ref-type="bibr">May et al., 2013</xref>).</p>
        <fig id="fig6" fig-type="figure" orientation="portrait" position="float">
          <?Figure Large?>
          <label>Figure 6.</label>
          <caption>
            <p><bold>Lymphocyte function.</bold> (A) IL-4 and IFN-Î³ production in the unstimulated situation and after stimulation with PMA/ionomycin in the LAT-mutated patient and a control (top). The graphs show the percentage of IL-4â (IL-4pos) and IFN-Î³âpositive (IFN-Î³pos) cells of CD4 CD45R0 T cells in patient 2 (red) compared with healthy day controls (blue). The standard deviation of 58 healthy controls is depicted in gray. IL-17 (bottom left) and IL-2 (bottom right) production after PMA/ionomycin (Iono) treatment in CD45R0 CD4 T cells of patient 2 and one or two controls, respectively. Numbers indicate the percentage of positive cells in the respective parental subpopulation (three independent experiments). (B) Up-regulation of CD69, ICOS, and CD25 in the LAT-mutated patient (red) and a control (blue) after stimulation with anti-CD3 (continuous line) and anti-CD3/anti-CD28 (dashed line). Results are representative of two independent experiments. (C) Proliferation of CD4 T cells after stimulation with anti-CD3, anti-CD3/anti-CD28, and PHA (two independent experiments). unst, unstimulated. (D) CTL degranulation is shown by the up-regulation of CD107a in CD8 T cells after stimulation with CD3/CD28 beads. (E) NK cell degranulation measured by the surface expression of CD107a after incubation of PBMCs with K562 target cells (two independent experiments). ctrl, control.</p>
          </caption>
          <graphic xlink:href="JEM_20151110_Fig6"/>
        </fig>
        <p>CD4 T cells of the heterozygous parents and one heterozygous sibling displayed normal up-regulation of CD69, ICOS, and CD25 T cells, normal percentage of IFN-Î³ and IL-17âproducing, but an increased percentage of IL-4âpositive CD4 T cells in the 9-yr-old sibling (20%). NK cell degranulation in the heterozygous sibling was within the range of healthy controls (not depicted).</p>
      </sec>
      <sec id="s09">
        <title>Î³Î´ T cells in LAT-mutated patient 2</title>
        <p>A common finding in all patients was the remarkable increase of Î³Î´ T cells. Î³Î´ T cells of patient 2 consisted of 24% CD8<sup>dim</sup> and 76% double-negative (CD4 negative/CD8 negative) Î³Î´ T cells, which is comparable to healthy controls. Unlike in healthy individuals, the most abundant circulating VÎ´2-positive Î³Î´ T cell population was nearly absent in patient 2 (<xref ref-type="fig" rid="fig7">Fig. 7 A</xref>), and in line with this finding, VÎ³9-positive cells were &lt;5% (not depicted). 25% of the patientâs Î³Î´ T cells expressed VÎ´1, indicating that 74% VÎ´1/VÎ´2-negative Î³Î´ T cells expressed VÎ´3, which could not be directly tested because of absent specific antibodies. Consistent with the findings in Î±Î² T cells, Ca<sup>2+</sup> mobilization was induced in Î³Î´ T cells after CD3 cross-linking and was comparable to healthy controls (<xref ref-type="fig" rid="fig7">Fig. 7 B</xref>).</p>
        <fig id="fig7" fig-type="figure" orientation="portrait" position="float">
          <?Figure Small?>
          <label>Figure 7.</label>
          <caption>
            <p><bold>Î³Î´ T cells in LAT mutation.</bold> (A) FACS plots of Î³Î´ and Î±Î² T cells in patient 2 and in a representative healthy control (top) and distribution of VÎ´1 versus VÎ´2 expression gated on Î³Î´ T cells (bottom). (B) Ca<sup>2+</sup> mobilization in Î³Î´ T cells in the patient and a control. The arrow indicates the addition of goat anti-mouse for CD3 cross-linking. The experiment was performed once. (C) Percentage of spontaneous IL-4 producer (IL-4pos) and IFN-Î³âpositive (IFN-Î³pos) Î³Î´ T cells after PMA/ionomycin stimulation in two independent experiments compared with three healthy controls each. ctrl, control.</p>
          </caption>
          <graphic xlink:href="JEM_20151110_Fig7"/>
        </fig>
        <p>As observed in healthy controls, most CD8-expressing Î³Î´ T cells produced IFN-Î³ upon PMA/ionomycin stimulation (not depicted). Among double-negative (CD4 negative/CD8 negative) Î³Î´ T cells, the number of spontaneous IL-4 producers was higher than in the controls, whereas IFN-Î³âpositive cell counts upon PMA/ionomycin stimulation were similar to healthy controls (<xref ref-type="fig" rid="fig7">Fig. 7 C</xref>), again showing the increase in the Th2 phenotype.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s10">
      <title>DISCUSSION</title>
      <p>Here, we describe the first kindred with a homozygous mutation in <italic>LAT</italic> presenting with a progressive combined immunodeficiency and profound immune dysregulation. All patients suffered from early onset autoimmune manifestations with normal lymphocyte counts and Ig levels. During the progression of the disease, the immune systems of the two older patients seemed to collapse, lymphocytopenia and hypogammaglobulinemia developed, and opportunistic as well as other infections occurred. The early death of patient 3 at 2 yr of age probably explains why she did not enter the second phase of the disease observed in her siblings. The mutation resulted in the expression of a truncated protein with a preserved extracellular and transmembrane region but lacking a large proportion of the intracellular adapter modules reported to be critically involved in TCR signaling pathways and T cell development in mice (<xref rid="bib40" ref-type="bibr">Sommers et al., 2001</xref>).</p>
      <p>LAT knockout mice (<xref rid="bib49" ref-type="bibr">Zhang et al., 1999b</xref>) and mice with targeted replacement of all four tyrosine residues (<xref rid="bib40" ref-type="bibr">Sommers et al., 2001</xref>) lack peripheral T cells because of a block at the double-negative 3 stage, whereas in humans, T cells lacking all four equivalent tyrosine residues were still present, although with a severely disturbed differentiation.</p>
      <p>In mice, site-directed mutation of the PLCÎ³1 recruitment site Y136 caused a partial block in TCRÎ±Î² T cell differentiation, and over time, these mice developed a lymphoproliferative disorder, systemic autoimmunity, eosinophilia, and elevated IgE and IgG1 levels caused by a prominent Th2 cytokine shift (<xref rid="bib2" ref-type="bibr">Aguado et al., 2002</xref>; <xref rid="bib41" ref-type="bibr">Sommers et al., 2002</xref>). This is reminiscent of our patients with regard to lymphoproliferation, autoimmunity, and increased IL-4 production in Î±Î² and Î³Î´ T cells of patient 2 (<xref rid="bib2" ref-type="bibr">Aguado et al., 2002</xref>; <xref rid="bib41" ref-type="bibr">Sommers et al., 2002</xref>; <xref rid="bib12" ref-type="bibr">Genton et al., 2006</xref>). The association of a Th2 skewing and a weak TCR signaling has been observed in other mouse models (<xref rid="bib8" ref-type="bibr">Corse et al., 2011</xref>) including an asthma model caused by low LAT-PLCÎ³1 interaction (<xref rid="bib30" ref-type="bibr">Peng et al., 2014</xref>). Also, in humans with impaired TCR signaling strength, this association with Th2 has been described (<xref rid="bib46" ref-type="bibr">Villa et al., 2008</xref>). In addition, effector T cells were generally expanded in the patient, including IFN-Î³âproducing T cells. An increased IFN-Î³ production upon stimulation compared with wild type has also been seen in the mouse LAT mutant models (<xref rid="bib2" ref-type="bibr">Aguado et al., 2002</xref>; <xref rid="bib41" ref-type="bibr">Sommers et al., 2002</xref>) and is probably an expression of the immune dysregulation and possibly infection in the patient. Mice with targeted mutations of the three distal tyrosine residues mY175, mY195, and mY235 developed an expansion of polyclonal Î³Î´ T cells in the spleen and in lymph nodes, reflecting the observation in the peripheral blood of our patients. However, in contrast to our LAT-deficient patients, in mice, the complete absence of LAT or the replacement of all four tyrosine residues of LAT abolished the emergence of Î³Î´ T cells in the periphery completely (<xref rid="bib40" ref-type="bibr">Sommers et al., 2001</xref>; <xref rid="bib27" ref-type="bibr">NuÃ±ez-Cruz et al., 2003</xref>). The expanded Î³Î´ T cell population in the examined patient predominantly expressed VÎ´3 and VÎ´1 chains, whereas the common VÎ´2 T cell compartment in healthy individuals (<xref rid="bib47" ref-type="bibr">Xiong and Raulet, 2007</xref>) was absent. Interestingly, the expansion of VÎ´3 T cells may contribute to the increased percentage of IL-4âproducing Î³Î´ T cells (<xref rid="bib23" ref-type="bibr">Mangan et al., 2013</xref>). A similar expansion of VÎ´1 and VÎ´3 T cells has been reported in CMV-seropositive patients after kidney and stem cell transplantation (<xref rid="bib9" ref-type="bibr">DÃ©chanet et al., 1999</xref>; <xref rid="bib19" ref-type="bibr">Knight et al., 2010</xref>), and a potential involvement of these cells in the anti-CMV immune response has been implied. Of note, patient 2 had CMV viremia, possibly contributing to the skewed VÎ´ usage seen in this patient.</p>
      <p>Thus, LAT-mutated mice and humans resemble each other with regard to severe immune dysregulation and lymphoproliferation associated with an expansion of Î³Î´ T cells and a disposition to a Th2 bias. Given the history of our patients, some of the differences compared with the mouse models like the emerging hypogammaglobulinemia and general lymphopenia might be secondary to infection and the increasing immune dysregulation, but the detectable development of mature T cells despite the absence of all four tyrosine signaling docking sites clearly demonstrates a difference between both species.</p>
      <p>We therefore analyzed the signaling downstream of the TCR in detail after having excluded a genetic reversion of the <italic>LAT</italic> mutation and alternative splicing of the mRNA. In mouse T cells and human T cell lines, LAT has been demonstrated to be essential for Ca<sup>2+</sup> mobilization and ERK phosphorylation after TCR stimulation (<xref rid="bib20" ref-type="bibr">Lin and Weiss, 2001</xref>; <xref rid="bib4" ref-type="bibr">Balagopalan et al., 2010</xref>). Thus, hY132/mY136 phosphorylation is required for the recruitment of PLCÎ³1, generation of IP<sub>3</sub>, and subsequent Ca<sup>2+</sup> mobilization in mouse T cells (<xref rid="bib50" ref-type="bibr">Zhang et al., 2000</xref>). Consistent with this finding, the expression of LAT<sup>wt</sup> but not LAT<sup>mut</sup> protein in LAT-deficient J.CaM2.5 cells was able to rescue Ca<sup>2+</sup> signaling. However, to our surprise, Ca<sup>2+</sup> mobilization after CD3 cross-linking was normal in primary T cells of the index patient, and the sustained T cell differentiation in LAT-deficient patients supports the notion of a preserved residual TCR signal in vivo.</p>
      <p>This discrepancy between human T cell lines and primary T cells might be caused by intrinsic differences in the signaling properties of cell lines and primary cells like the absence of the phosphatases PTEN (phosphatase and tensin homolog) and SHIP-1 in Jurkat cells (<xref rid="bib1" ref-type="bibr">Abraham and Weiss, 2004</xref>) or the presence of alternative transmembrane adapters replacing LAT function in primary T cells. SIT (<xref rid="bib24" ref-type="bibr">Marie-Cardine et al., 1999</xref>), TRIM (<xref rid="bib7" ref-type="bibr">Bruyns et al., 1998</xref>), LAX (<xref rid="bib51" ref-type="bibr">Zhu et al., 2002</xref>), LIME (<xref rid="bib6" ref-type="bibr">BrdiÄkovÃ¡ et al., 2003</xref>; <xref rid="bib16" ref-type="bibr">Hur et al., 2003</xref>), and PAG (<xref rid="bib43" ref-type="bibr">Stepanek et al., 2014</xref>) share structural features with LAT but are expressed in both primary T cells and in Jurkat cells. Moreover, they were not differentially expressed in the primary cells of the index patient compared with controls on the RNA level, rendering the functional substitution for LAT unlikely. NTAL/LAB is not expressed in normal resting T cells (<xref rid="bib5" ref-type="bibr">BrdiÄka et al., 2002</xref>) but might be up-regulated in activated T cells (<xref rid="bib52" ref-type="bibr">Zhu et al., 2006</xref>), and LAB expression can partially restore Ca<sup>2+</sup> flux in LAT-deficient J.CaM2.5 cells (<xref rid="bib17" ref-type="bibr">Janssen et al., 2004</xref>). However, we could not detect protein expression in primary T cells of our patient and therefore did not follow up on this protein. Based on the different expression patterns in primary T cells and the J.CaM2.5 cell line, the most potent candidate was CD6, which associates, like LAT, with SLP76 in an activation-dependent manner (<xref rid="bib34" ref-type="bibr">Roncagalli et al., 2014</xref>). However, in J.CaM2.5 cells and in J.CaM2.5-LAT<sup>mut</sup> cells, the induced expression of CD6 was not sufficient to elicit Ca<sup>2+</sup> mobilization upon TCR stimulation. Therefore, it is unlikely that CD6 replaces LAT function in LAT-deficient primary T cells, and the explanation of the preserved Ca<sup>2+</sup> flux, NF-ÎºB activation in the patientâs T cells, and the persistent T cell differentiation remains elusive at this time.</p>
      <p>In contrast to Ca<sup>2+</sup> mobilization, ERK phosphorylation and the up-regulation of CD69 were abolished in primary LAT<sup>mut</sup>-expressing T cells and in LAT-deficient and LAT<sup>mut</sup>-expressing J.CaM2.5 cells. A functional Ca<sup>2+</sup> response but defective ERK signaling in the patientâs T cells could be explained by several mechanisms. First, if the LAT-substituting protein allowed TCR-induced activation of PLCÎ³1, IP<sub>3</sub> and diacylglycerol (DAG) would be produced. IP<sub>3</sub> would cause Ca<sup>2+</sup> influx, but DAG would not be sufficient to activate ERK. Indeed, using primary human T cells, it was shown that both Ras-activating proteins RasGRP1 (downstream of DAG) and SOS1 are required to activate Ras and thus the ERK pathway after an activating TCR trigger (<xref rid="bib31" ref-type="bibr">Poltorak et al., 2014</xref>). In fact, LAT tyrosine residues hY171/mY175, hY191/mY195, and hY226/mY235 are indispensable in recruiting Grb2-SOS1 to the membrane activating the ERK pathway (<xref rid="bib11" ref-type="bibr">Finco et al., 1998</xref>; <xref rid="bib48" ref-type="bibr">Zhang et al., 1999a</xref>; <xref rid="bib40" ref-type="bibr">Sommers et al., 2001</xref>; <xref rid="bib4" ref-type="bibr">Balagopalan et al., 2010</xref>). In this scenario, the LAT-substituting protein would not recruit Grb2. Hence, our finding again corroborates the nonredundant role for hY171/mY175, hY191/mY195, and hY226/mY235 in the activation of ERK (<xref rid="bib4" ref-type="bibr">Balagopalan et al., 2010</xref>; <xref rid="bib31" ref-type="bibr">Poltorak et al., 2014</xref>) in humans and mice. Second, IP<sub>3</sub> and DAG would be produced in the patientâs T cells, but highly active DAG kinases (DGKs), such as DGKÎ± and DGKÎ¶ (<xref rid="bib18" ref-type="bibr">Joshi and Koretzky, 2013</xref>), would remove DAG so that RasGRP1 could not be activated and, subsequently, Ras would stay inactive. Because we did not find enhanced transcript levels for DGKÎ± and DGKÎ¶ in the patientâs T cells (unpublished data), we find this possibility less likely.</p>
      <p>The observed alteration but not absence of TCR-induced signaling illuminates the phenotype, which resembles more the mouse phenotype of LAT signaling pathology in specific LAT mutations than the severe T cell deficiency in knockout mice. Although first proposed to result from defective positive selection and subsequent expansion of autoreactive T cells (<xref rid="bib42" ref-type="bibr">Sommers et al., 2005</xref>), <xref rid="bib33" ref-type="bibr">Roncagalli et al. (2010)</xref> subsequently suggested that hyperactivation of normal T cells triggered by peptideâMHC complexes leads to uncontrolled lymphoproliferation and immune dysregulation. Thus, the clinical presentation of human LAT deficiency resembles previously described immunodeficiencies caused by other alterations in TCR signaling like in ZAP70, ITK, or lymphocyte-specific protein tyrosine kinase (LCK) deficiency, all of which are interaction partners of LAT. Despite the immunological resemblance, especially to LCK deficiency, there are clearly distinct features like the prominent reduction of CD8 T cells in ZAP70 deficiency (<xref rid="bib32" ref-type="bibr">Roifman et al., 2010</xref>), the absent Ca<sup>2+</sup> signal in ITK deficiency (<xref rid="bib21" ref-type="bibr">Linka et al., 2012</xref>), and the preserved ERK signal in LCK deficiency (<xref rid="bib14" ref-type="bibr">Hauck et al., 2012</xref>) highlighting the complex regulation of the signaling and subsequent effect on T cell differentiation.</p>
      <p>Given the severe clinical phenotype and high mortality resulting from the profound combined immunodeficiency and immune dysregulation observed in human LAT deficiency, hematopoietic stem cell transplantation of the index patient was performed. The 1-yr follow-up demonstrated full donor chimerism, resolution of opportunistic infections and autoimmune cytopenias, and disappearance of skin infiltrates without any immunosuppressive treatment. The identification of additional patients with possibly different LAT mutations will shed further light on the full immunological and clinical presentation of human LAT deficiency.</p>
    </sec>
    <sec sec-type="materials|methods" id="s11">
      <title>MATERIALS AND METHODS</title>
      <sec id="s12">
        <title/>
        <sec id="s13">
          <title>Patients</title>
          <p>The medical records of three siblings, two males and one female, from one Israeli Arab consanguineous kindred were reviewed for data on clinical presentation, immunological features, genetic findings, treatment, and final outcome. All experiments were performed after obtaining parental written informed consent and approval by the Hadassah and Israeli Ministry of Health ethical review boards.</p>
        </sec>
        <sec id="s14">
          <title>Antibodies used in this study</title>
          <p>The following antibodies were used in this study: CD3 AF700, CD4 BV421, CD4 FITC, CD6 APC, CD10 BV605, CD19 APC-Cy7, CD21 PE-Cy7, CD25 PerCP-Cy5.5, CD27 BV421, CD28 PerCP-Cy5.5, CD38 PerCp-Cy5.5, CD45RA APC-Cy7, TCR Î±Î² PerCP-Cy5.5, IL-2 PE, LAT PE, NTAL/LAB APC, and biotin antiâhuman TCR-Vd2 (BioLegend); TCR-Vd1 APC (Miltenyi Biotec); CD8 APC, CD8 Pacific blue, CD21 PE-Cy7, CD31 PE, CD56 APC, CD69 FITC, CD107a PE, CD127 Alexa Fluor 647, IFN-Î³ FITC, TCR Î³Î´ PE, IgG Alexa Fluor 700, IÎºBÎ± PE, ERK1/2(pT202/pY204) AF647, and ZAP70(pY319)/SYK(pY352) APC (BD); IgD FITC and IgA PE (SouthernBiotech); CD3 PE-Cy7, CD4 PE-Cy7, CD8 PE, CD16 FITC, CD45RA FITC, CD45 Pacific blue, VÎ±24 PE, and VÎ²11 FITC (Beckman Coulter); CCR7 PE (R&amp;D Systems); Bruton tyrosine kinase/ITK(pY551/pY511) PE, IL-17 PE, IL-4 APC, and ICOS PE (eBioscience); IgM Alexa Fluor 647 (Jackson ImmunoResearch Laboratories, Inc.); and PLCÎ³1(pY783) and goat antiârabbit AF647 (Cell Signaling Technology). For immunohistochemistry, CD21 (Dako), CD20 (Invitrogen), CD3 (Cell Marque), CD4 and CD8 (Spring Bioscience), and Bcl-6 (Leica Biosystems) were used. For immunoblotting LAT (sc-7948; Santa Cruz Biotechnology, Inc.), FLAG tag (AHP1074; AbD Serotec), actin (sc-1616; Santa Cruz Biotechnology, Inc.), PLCÎ³1 (pY783; no. 2821; Cell Signaling Technology), and ZAP70 (pY319; no. 2701; Cell Signaling Technology) were used.</p>
        </sec>
        <sec id="s15">
          <title>Whole exome sequencing</title>
          <p>Exonic sequences were enriched in the DNA sample of our patient 2 using the SureSelect Human All Exon 50 Mb kit (Agilent Technologies). Sequences were determined by HiSeq2000 (Illumina) as 100-bp paired-end runs. Data analysis including read alignment and variant calling was performed by DNAnexus software using the default parameters with the human genome assembly (hg19; GRCh37) as a reference as previously described (<xref rid="bib44" ref-type="bibr">Stepensky et al., 2013</xref>). For confirmation of the identified mutation, Sanger sequencing was performed in the index patient, his parents, and two deceased and two living siblings.</p>
        </sec>
        <sec id="s16">
          <title>Molecular biology</title>
          <p>LAT transcript was examined in EBV lines of the index patient and healthy controls. RNA was isolated using the RNeasy Plus Mini kit (QIAGEN), and cDNA was generated by using a Superscript II reverse transcription (Thermo Fisher Scientific). PCR or quantitative PCR using SYBR green I master mix (Roche) was performed with primer pairs spanning exon 1â3 (forward, 5â²-TGTTGATGGCACTGTGTGTG-3â²; reverse, 5â²-TGGGTAGGAGGTGACAGGTG-3â²) or full-length LAT covering exon 1â10 (forward, 5â²-GTATCCAAGGGGCATCCAGTT-3â²; reverse, 5â²-CCTCTTCCTCCACTTCCTCTG-3â²) and hypoxanthine phosphoribosyltransferase (forward, 5â²-TCAGGCAGTATAATCCAAAGATGGT-3â²; reverse, 5â²-AGTCTGGCTTATATCCAACACTTCG-3â²). Genomic DNA was isolated using the QIAamp DNA Mini kit (QIAGEN). For Sanger sequencing on guide DNA of isolated CD4 CD45R0 T cells, primers in intron 4 (forward, 5â²-CTTTCCCTTTTGCAACTGCT-3â²) and intron 5 (reverse, 5â²-TTCCCCACACTTACCACCAT-3â²) of <italic>LAT</italic> were designed covering exon 5. For the exclusion of alternative splice variants, primers were designed located in LAT exon 4 (forward, 5â²-CTACCCACCTGTCACCTCCTAC-3â²), exon 7 (forward, 5â²-ATAGTCGTCCTCATCCTCATCC-3â²), and exon 10 (reverse, 5â²-TTCCTGGGACACATTCACATAC-3â²).</p>
        </sec>
        <sec id="s17">
          <title>RNA sequencing</title>
          <p>Cells were sorted from control and patient samples into RLT buffer (QIAGEN). Total RNA was isolated using the RNeasy Micro kit (QIAGEN) according to manufacturerâs recommendations. cDNA was generated using an Ovation RNA-Seq system (V2; NuGEN), and libraries were constructed with an Ovation Ultralow system (V2 1â16; NuGEN) according to the manufacturerâs instructions. The libraries were subjected to 50 cycles of NextSeq 500 sequencing.</p>
          <p>Data analysis was performed with RNAExpress (Illumina), which performed alignment of reads to the human reference genome (hg19; University of California, Santa Cruz) using the STAR aligner and determined differentially expressed genes using DESeq2.</p>
        </sec>
        <sec id="s18">
          <title>Cloning of FLAG-tagged wild-type and mutant LAT and CD6 and expression in LAT-deficient J.CaM2.5 cells</title>
          <p>The human LAT and CD6 cDNAs were provided by the BIOSS Toolbox (human ORFeome V5.1 collection; clones 7273 and 14950; GE Healthcare). Wild-type LAT was amplified from cDNA by a single PCR (forward primer, 5â²-TCCGATTGACTGAGTCGCCCGGATCCGCCACCATGGAGGAGGCCATCCTG-3â²; reverse primer, 5â²-GGGGGGAGAGGGGCGGAATTCTCATTTGTCGTCGTCGTCTTTGTAGTCGTTCAGCTCCTGCAGATTCTC-3â²) and mutant LAT by two consecutive PCRs (both with forward primers as for wild-type LAT; reverse primer for the first PCR, 5â²-CCCAAGGGGCTGCG-3â²; reverse primer for the second PCR, 5â²-GGGGGGAGAGGGGCGGAATTCTCATTTGTCGTCGTCGTCTTTGTAGTCGAATCCCGCCGGGAAGATGGCGTCCGGTGGGAGCCCAAGGGGCTGCG-3â²). Both wild-type and mutant LAT amplicons were cloned into BamHIâEcoRI-digested pLVX-S IZ (<xref rid="bib10" ref-type="bibr">Dopfer et al., 2014</xref>) by the <xref rid="bib13" ref-type="bibr">Gibson et al. (2009)</xref> assembly method. HEK 293 T cells were transfected with either pLVX-S IZ LAT-FLAG wild type or mutant, together with the packaging plasmids pMD2 vsv.G and pCMV dR8.74. Cell culture supernatants containing lentiviral particles were collected 48 h after transfection and used to infect the LAT-deficient J.CaM2.5 cells. The transduced cells were sorted for the same ZsGreen1 expression. Similarly, CD6 was amplified (forward primer, 5â²-CCGGATCTATTTCCGGTGAATTCCTCGAGACTAGTGCCACCATGTGGCTCTTCTTCGGGATC-3â²; reverse primer, 5â²-AGGGGCGGAATTGGATCCGCGGCCGCCTAGGCTGCGCTGATGTCAT-3â²) and cloned into NotIâSpeI-digested pLVX-S IP (<xref rid="bib10" ref-type="bibr">Dopfer et al., 2014</xref>). Lentiviral particles were produced as described in this paragraph and used to transduce J.CaM2.5, J.CaM2.5-LAT<sup>mut</sup>, and J.CaM2.5-LAT<sup>wt</sup> cells. FACS staining revealed transduction efficacy of 40â60% stably expressing CD6. Cultivation in puromycin was used for selection of transduced cells.</p>
        </sec>
        <sec id="s19">
          <title>Immunoblotting</title>
          <p>For the detection of LAT by immunoblotting, J.CaM2.5, J.CaM2.5-LAT<sup>wt</sup>, or J.CaM2.5-LAT<sup>mut</sup> cells were lysed, insoluble parts were removed by centrifugation, and the proteins were separated by SDS-PAGE and detected by immunoblotting according to standard protocols via the C-terminal FLAG tag. To measure phosphorylation of PLCÎ³1(pY783) and ZAP70(pY319), 10<sup>6</sup> J.CaM2.5, J.CaM2.5-LAT<sup>wt</sup>, and J.CaM2.5-LAT<sup>mut</sup> cells were stimulated with 5 Âµg/ml anti-CD3 (UCHT1) for 3 min at 37Â°C or left untreated, total cell lysates were separated as before, and protein phosphorylation was detected by immunoblotting using phosphospecific antibodies.</p>
        </sec>
        <sec id="s20">
          <title>Cell isolation and cultivation</title>
          <p>PBMCs were isolated from EDTA blood by Ficoll density gradient centrifugation following standard protocols. CD45R0 CD4 T cells were isolated using a memory CD4<sup>+</sup> T cell isolation kit (Miltenyi Biotech) according to the manufacturerâs instructions. LAT-deficient J.CaM2.5 cells and primary PBMCs were cultivated in RPMI 1640 (PAN Biotech) containing 10% FCS, 1% penicillin, and 1% streptomycin.</p>
        </sec>
        <sec id="s21">
          <title>Ca<sup>2+</sup> mobilization</title>
          <p>To analyze Ca<sup>2+</sup> mobilization, cells were labeled with 4.5 ÂµM Indo-1 and 0.045% Pluronic F-127 (Thermo Fisher Scientific) for 45 min at room temperature. Cells were washed twice, and for primary cells, cell surface staining for CD4, CD8, and CD45RA or additionally TCR Î³Î´ was performed for 15 min at room temperature. Ca<sup>2+</sup> mobilization was determined after incubation with 5 and 0.6 Âµg/ml anti-CD3 (UCHT1; BD) for 10 min at room temperature. Data acquisition was performed on a cell analyzer (LSR Fortessa; BD). After baseline acquisition for 45 s, cross-linking was performed with 5 Âµg/ml goat antiâmouse IgG (Jackson ImmunoResearch Laboratories, Inc.). Ionomycin (Sigma-Aldrich) was added as a positive control. J.CaM2.5 cells were stimulated by adding 5 Âµg/ml anti-CD3 (OKT3) or 5 Âµg/ml anti-CD3 and preincubated with goat antiâmouse IgG for 30 min at 4Â°C after a 30-s baseline acquisition. Ca<sup>2+</sup> flux was recorded for 5 min before ionomycin was added as a loading control.</p>
        </sec>
        <sec id="s22">
          <title>Signaling assays</title>
          <p>For intracellular flow cytometry, cells were incubated with 5 Âµg/ml anti-CD3 (OKT3) with or without 5 Âµg/ml anti-CD28 for 30 min on ice. 5 Âµg/ml goat antiâmouse IgG was added for an additional 30 min. J.CaM2.5 cells were stimulated with 5 Âµg/ml anti-CD3 (OKT3). For detection of ZAP70(pY319), Bruton tyrosine kinase/ITK(pY551/pY511), PLCÎ³1(pY783), and ERK1/2(pT202/pY204) cells were stimulated for 2 min with anti-CD3 and for S6(pS235/pS236) and IÎºBÎ±, for 30 min with anti-CD3/anti-CD28. Immediately after stimulation, cells were fixed and subsequently permeabilized using the Phosflow intracellular staining kit (BD) according to the manufacturerâs instructions. Cells were stained with the respective antibodies.</p>
        </sec>
        <sec id="s23">
          <title>Cytokine production</title>
          <p>Intracellular cytokines were determined after stimulation of PBMCs with 10 Âµg/ml anti-CD3 (OKT3) and 2 Âµg/ml anti-CD28 (Sanquin) or 5 ng/ml PMA and 0.75 Âµg/ml ionomycin in the presence of 10 Âµg/ml brefeldin A (all from Sigma-Aldrich). After 4 h, cells were harvested, and fixation and permeabilization was performed using a staining kit for intracellular cytokines (BD) according to the manufacturerâs protocol, and after surface and intracellular staining for 20 min, the cells were analyzed by flow cytometry.</p>
        </sec>
        <sec id="s24">
          <title>T cell activation and proliferation</title>
          <p>For T cell activation, 2 Ã 10<sup>5</sup> cells were stimulated with plate-bound anti-CD3 (OKT3) or anti-CD3/anti-CD28 for 16 h at 37Â°C. Cell lines were stimulated with 5 Âµg/ml of soluble anti-CD3 (OKT3) for 6â16 h. Subsequently, cells were harvested and stained with the corresponding antibodies. For T cell proliferation, PBMCs were labeled with 0.5 ÂµM CFSE (Thermo Fisher Scientific) according to the manufacturerâs instructions. Cells were left untreated or stimulated with 1 Âµg/ml of plate-bound anti-CD3 or 0.3 Âµg/ml anti-CD3 and 0.5 Âµg/ml of soluble anti-CD28 or PHA for 5 d at 37Â°C. Cells were harvested and stained for CD4 and CD8.</p>
        </sec>
        <sec id="s25">
          <title>NK cell degranulation</title>
          <p>2 Ã 10<sup>5</sup> PBMCs were mixed with 2 Ã 10<sup>5</sup> target cells of the human erythroleukemia cell line K562 (American Type Culture Collection) in Iscoveâs modified Dulbeccoâs medium (Thermo Fisher Scientific) containing 10% FCS. Cells were spun down for 3 min at 30 <italic>g</italic> and stimulated for 2 h at 37Â°C. After stimulation, cells were harvested and stained with the corresponding antibodies for flow cytometry to determine CD107 up-regulation on CD56<sup>+</sup> CD3<sup>â</sup> NK cells, correlating with target cell lysis.</p>
        </sec>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGMENTS</title>
      <p>The authors would like to thank Iris Porat, Carmit Lugasy, Ina Stumpf, Liselotte Lenner, the Advanced Diagnostics unit of the Center for Chronic Immunodeficiency, and the BIOSS toolbox for excellent technical assistance. We also thank the team of the Department of Pediatric Hematology Oncology of Ruth Rappaport Children's Hospital for the treatment of the child and the family of the patient for their trust and support. We also thank Burkhart Schraven and Luca Simeoni for discussions.</p>
      <p>B. Keller, O.S. Yousefi, S. Unger, W.W. Schamel, and K. Warnatz were supported by the German Federal Ministry of Education and Research (BMBF 01EO1303). P. Stepensky and K. Warnatz received funding from the Deutsche Forschungsgemeinschaft (Discovery and Evaluation of New Combined Immunodeficiency Disease Entities; grant DFG WA 1597/4-1). P. Stepensky was supported by a research grant from the joint fund of the Hebrew University and Hadassah Medical Center. This study was supported in part by the Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School).</p>
      <p>The authors declare no competing financial interests.</p>
    </ack>
    <fn-group>
      <fn id="fnd0e7243">
        <p>
<def-list><title>Abbreviations used:</title><def-item><term>DAG</term><def><p>diacylglycerol</p></def></def-item><def-item><term>DGK</term><def><p>DAG kinase</p></def></def-item><def-item><term>ERK</term><def><p>extracellular signal-regulated kinase</p></def></def-item><def-item><term>ICOS</term><def><p>inducible T cell co-stimulator</p></def></def-item><def-item><term>IP<sub>3</sub></term><def><p>inositol 1,4,5-trisphosphate</p></def></def-item><def-item><term>ITK</term><def><p>IL-2âinducible T cell kinase</p></def></def-item><def-item><term>LAB</term><def><p>linker for activation of B cells</p></def></def-item><def-item><term>LAT</term><def><p>linker for activation of T cells</p></def></def-item><def-item><term>NTAL</term><def><p>nonâT cell activation linker</p></def></def-item></def-list>
</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="bib1">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>R.T.</given-names></name>, and <name name-style="western"><surname>Weiss</surname><given-names>A.</given-names></name></person-group>
<year>2004</year>
<article-title>Jurkat T cells and development of the T-cell receptor signalling paradigm</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>4</volume>:<fpage>301</fpage>â<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1038/nri1330</pub-id><pub-id pub-id-type="pmid">15057788</pub-id></mixed-citation>
      </ref>
      <ref id="bib2">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguado</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Richelme</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>NuÃ±ez-Cruz</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Miazek</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mura</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Richelme</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>X.J.</given-names></name>, <name name-style="western"><surname>Sainty</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>H.T.</given-names></name>, <name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name>, and <name name-style="western"><surname>Malissen</surname><given-names>M.</given-names></name></person-group>
<year>2002</year>
<article-title>Induction of T helper type 2 immunity by a point mutation in the LAT adaptor</article-title>. <source>Science.</source>
<volume>296</volume>:<fpage>2036</fpage>â<lpage>2040</lpage>. <pub-id pub-id-type="doi">10.1126/science.1069057</pub-id><pub-id pub-id-type="pmid">12065839</pub-id></mixed-citation>
      </ref>
      <ref id="bib3">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Archambaud</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sansoni</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mingueneau</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Devilard</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Delsol</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name>, and <name name-style="western"><surname>Malissen</surname><given-names>M.</given-names></name></person-group>
<year>2009</year>
<article-title>STAT6 deletion converts the Th2 inflammatory pathology afflicting <italic>Lat<sup>Y136F</sup></italic> mice into a lymphoproliferative disorder involving Th1 and CD8 effector T cells</article-title>. <source>J. Immunol.</source>
<volume>182</volume>:<fpage>2680</fpage>â<lpage>2689</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0803257</pub-id><pub-id pub-id-type="pmid">19234162</pub-id></mixed-citation>
      </ref>
      <ref id="bib4">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balagopalan</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Coussens</surname><given-names>N.P.</given-names></name>, <name name-style="western"><surname>Sherman</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Samelson</surname><given-names>L.E.</given-names></name>, and <name name-style="western"><surname>Sommers</surname><given-names>C.L.</given-names></name></person-group>
<year>2010</year>
<article-title>The LAT story: a tale of cooperativity, coordination, and choreography</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source>
<volume>2</volume>:<fpage>a005512</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a005512</pub-id><pub-id pub-id-type="pmid">20610546</pub-id></mixed-citation>
      </ref>
      <ref id="bib5">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>BrdiÄka</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Imrich</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>AngelisovÃ¡</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>BrdiÄkovÃ¡</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>HorvÃ¡th</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Å piÄka</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Hilgert</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>LuskovÃ¡</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>DrÃ¡ber</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>NovÃ¡k</surname><given-names>P.</given-names></name>, <etal/></person-group>
<year>2002</year>
<article-title>NonâT cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling</article-title>. <source>J. Exp. Med.</source>
<volume>196</volume>:<fpage>1617</fpage>â<lpage>1626</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20021405</pub-id><pub-id pub-id-type="pmid">12486104</pub-id></mixed-citation>
      </ref>
      <ref id="bib6">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>BrdiÄkovÃ¡</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>BrdiÄka</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>AngelisovÃ¡</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>HorvÃ¡th</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Å piÄka</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Hilgert</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>PaÄes</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Simeoni</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Kliche</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Merten</surname><given-names>C.</given-names></name>, <etal/></person-group>
<year>2003</year>
<article-title>LIME: a new membrane Raft-associated adaptor protein involved in CD4 and CD8 coreceptor signaling</article-title>. <source>J. Exp. Med.</source>
<volume>198</volume>:<fpage>1453</fpage>â<lpage>1462</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20031484</pub-id><pub-id pub-id-type="pmid">14610046</pub-id></mixed-citation>
      </ref>
      <ref id="bib7">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruyns</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Marie-Cardine</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kirchgessner</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Sagolla</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Shevchenko</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mann</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Autschbach</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Bensussan</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Meuer</surname><given-names>S.</given-names></name>, and <name name-style="western"><surname>Schraven</surname><given-names>B.</given-names></name></person-group>
<year>1998</year>
<article-title>T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCRâCD3âÎ¶ complex, recruits intracellular signaling proteins to the plasma membrane</article-title>. <source>J. Exp. Med.</source>
<volume>188</volume>:<fpage>561</fpage>â<lpage>575</lpage>. <pub-id pub-id-type="doi">10.1084/jem.188.3.561</pub-id><pub-id pub-id-type="pmid">9687533</pub-id></mixed-citation>
      </ref>
      <ref id="bib8">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corse</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Gottschalk</surname><given-names>R.A.</given-names></name>, and <name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name></person-group>
<year>2011</year>
<article-title>Strength of TCR-peptide/MHC interactions and in vivo T cell responses</article-title>. <source>J. Immunol.</source>
<volume>186</volume>:<fpage>5039</fpage>â<lpage>5045</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1003650</pub-id><pub-id pub-id-type="pmid">21505216</pub-id></mixed-citation>
      </ref>
      <ref id="bib9">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DÃ©chanet</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Merville</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>RetiÃ¨re</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Pitard</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Lafarge</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Michelson</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>MÃ©ric</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Hallet</surname><given-names>M.M.</given-names></name>, <name name-style="western"><surname>Kourilsky</surname><given-names>P.</given-names></name>, <etal/></person-group>
<year>1999</year>
<article-title>Implication of Î³Î´ T cells in the human immune response to cytomegalovirus</article-title>. <source>J. Clin. Invest.</source>
<volume>103</volume>:<fpage>1437</fpage>â<lpage>1449</lpage>. <pub-id pub-id-type="doi">10.1172/JCI5409</pub-id><pub-id pub-id-type="pmid">10330426</pub-id></mixed-citation>
      </ref>
      <ref id="bib10">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dopfer</surname><given-names>E.P.</given-names></name>, <name name-style="western"><surname>Hartl</surname><given-names>F.A.</given-names></name>, <name name-style="western"><surname>Oberg</surname><given-names>H.H.</given-names></name>, <name name-style="western"><surname>Siegers</surname><given-names>G.M.</given-names></name>, <name name-style="western"><surname>Yousefi</surname><given-names>O.S.</given-names></name>, <name name-style="western"><surname>Kock</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Fiala</surname><given-names>G.J.</given-names></name>, <name name-style="western"><surname>GarcillÃ¡n</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Sandstrom</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>AlarcÃ³n</surname><given-names>B.</given-names></name>, <etal/></person-group>
<year>2014</year>
<article-title>The CD3 conformational change in the Î³Î´ T cell receptor is not triggered by antigens but can be enforced to enhance tumor killing</article-title>. <source>Cell Reports.</source>
<volume>7</volume>:<fpage>1704</fpage>â<lpage>1715</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2014.04.049</pub-id><pub-id pub-id-type="pmid">24857663</pub-id></mixed-citation>
      </ref>
      <ref id="bib11">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finco</surname><given-names>T.S.</given-names></name>, <name name-style="western"><surname>Kadlecek</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Samelson</surname><given-names>L.E.</given-names></name>, and <name name-style="western"><surname>Weiss</surname><given-names>A.</given-names></name></person-group>
<year>1998</year>
<article-title>LAT is required for TCR-mediated activation of PLCÎ³1 and the Ras pathway</article-title>. <source>Immunity.</source>
<volume>9</volume>:<fpage>617</fpage>â<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(00)80659-7</pub-id><pub-id pub-id-type="pmid">9846483</pub-id></mixed-citation>
      </ref>
      <ref id="bib12">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genton</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Izui</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Delsol</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>FourniÃ©</surname><given-names>G.J.</given-names></name>, <name name-style="western"><surname>Malissen</surname><given-names>M.</given-names></name>, and <name name-style="western"><surname>Acha-Orbea</surname><given-names>H.</given-names></name></person-group>
<year>2006</year>
<article-title>The Th2 lymphoproliferation developing in <italic>Lat<sup>Y136F</sup></italic> mutant mice triggers polyclonal B cell activation and systemic autoimmunity</article-title>. <source>J. Immunol.</source>
<volume>177</volume>:<fpage>2285</fpage>â<lpage>2293</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.177.4.2285</pub-id><pub-id pub-id-type="pmid">16887989</pub-id></mixed-citation>
      </ref>
      <ref id="bib13">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibson</surname><given-names>D.G.</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Chuang</surname><given-names>R.Y.</given-names></name>, <name name-style="western"><surname>Venter</surname><given-names>J.C.</given-names></name>, <name name-style="western"><surname>Hutchison</surname><given-names>C.A.</given-names><suffix>III</suffix></name>, and <name name-style="western"><surname>Smith</surname><given-names>H.O.</given-names></name></person-group>
<year>2009</year>
<article-title>Enzymatic assembly of DNA molecules up to several hundred kilobases</article-title>. <source>Nat. Methods.</source>
<volume>6</volume>:<fpage>343</fpage>â<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1318</pub-id><pub-id pub-id-type="pmid">19363495</pub-id></mixed-citation>
      </ref>
      <ref id="bib14">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauck</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Randriamampita</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Gerart</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lambert</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Soulier</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Maciorowski</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Touzot</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Moshous</surname><given-names>D.</given-names></name>, <etal/></person-group>
<year>2012</year>
<article-title>Primary T-cell immunodeficiency with immunodysregulation caused by autosomal recessive LCK deficiency</article-title>. <source>J. Allergy Clin. Immunol.</source>
<volume>130</volume>:<fpage>1144</fpage>â<lpage>1152.e11</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2012.07.029</pub-id><pub-id pub-id-type="pmid">22985903</pub-id></mixed-citation>
      </ref>
      <ref id="bib15">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holst</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Eder</surname><given-names>K.D.</given-names></name>, <name name-style="western"><surname>Workman</surname><given-names>C.J.</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>K.L.</given-names></name>, <name name-style="western"><surname>Baquet</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Forbes</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Chruscinski</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Smeyne</surname><given-names>R.</given-names></name>, <etal/></person-group>
<year>2008</year>
<article-title>Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity</article-title>. <source>Nat. Immunol.</source>
<volume>9</volume>:<fpage>658</fpage>â<lpage>666</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1611</pub-id><pub-id pub-id-type="pmid">18469818</pub-id></mixed-citation>
      </ref>
      <ref id="bib16">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hur</surname><given-names>E.M.</given-names></name>, <name name-style="western"><surname>Son</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>O.H.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>Y.B.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name>, and <name name-style="western"><surname>Yun</surname><given-names>Y.</given-names></name></person-group>
<year>2003</year>
<article-title>LIME, a novel transmembrane adaptor protein, associates with p56<sup>lck</sup> and mediates T cell activation</article-title>. <source>J. Exp. Med.</source>
<volume>198</volume>:<fpage>1463</fpage>â<lpage>1473</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20030232</pub-id><pub-id pub-id-type="pmid">14610044</pub-id></mixed-citation>
      </ref>
      <ref id="bib17">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janssen</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Craven</surname><given-names>B.</given-names></name>, and <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group>
<year>2004</year>
<article-title>Linker for activation of B cells: a functional equivalent of a mutant linker for activation of T cells deficient in phospholipase C-Î³1 binding</article-title>. <source>J. Immunol.</source>
<volume>172</volume>:<fpage>6810</fpage>â<lpage>6819</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.172.11.6810</pub-id><pub-id pub-id-type="pmid">15153499</pub-id></mixed-citation>
      </ref>
      <ref id="bib18">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>R.P.</given-names></name>, and <name name-style="western"><surname>Koretzky</surname><given-names>G.A.</given-names></name></person-group>
<year>2013</year>
<article-title>Diacylglycerol kinases: regulated controllers of T cell activation, function, and development</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>14</volume>:<fpage>6649</fpage>â<lpage>6673</lpage>. <pub-id pub-id-type="doi">10.3390/ijms14046649</pub-id><pub-id pub-id-type="pmid">23531532</pub-id></mixed-citation>
      </ref>
      <ref id="bib19">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knight</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Madrigal</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Grace</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sivakumaran</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Kottaridis</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Mackinnon</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Travers</surname><given-names>P.J.</given-names></name>, and <name name-style="western"><surname>Lowdell</surname><given-names>M.W.</given-names></name></person-group>
<year>2010</year>
<article-title>The role of VÎ´2-negative Î³Î´ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation</article-title>. <source>Blood.</source>
<volume>116</volume>:<fpage>2164</fpage>â<lpage>2172</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2010-01-255166</pub-id><pub-id pub-id-type="pmid">20576814</pub-id></mixed-citation>
      </ref>
      <ref id="bib20">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name>, and <name name-style="western"><surname>Weiss</surname><given-names>A.</given-names></name></person-group>
<year>2001</year>
<article-title>Identification of the minimal tyrosine residues required for linker for activation of T cell function</article-title>. <source>J. Biol. Chem.</source>
<volume>276</volume>:<fpage>29588</fpage>â<lpage>29595</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M102221200</pub-id><pub-id pub-id-type="pmid">11395491</pub-id></mixed-citation>
      </ref>
      <ref id="bib21">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linka</surname><given-names>R.M.</given-names></name>, <name name-style="western"><surname>Risse</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Bienemann</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Werner</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Linka</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Krux</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Synaeve</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Deenen</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ginzel</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Dvorsky</surname><given-names>R.</given-names></name>, <etal/></person-group>
<year>2012</year>
<article-title>Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases</article-title>. <source>Leukemia.</source>
<volume>26</volume>:<fpage>963</fpage>â<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1038/leu.2011.371</pub-id><pub-id pub-id-type="pmid">22289921</pub-id></mixed-citation>
      </ref>
      <ref id="bib22">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>GrÃ©goire</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Malissen</surname><given-names>M.</given-names></name>, and <name name-style="western"><surname>Roncagalli</surname><given-names>R.</given-names></name></person-group>
<year>2014</year>
<article-title>Integrative biology of T cell activation</article-title>. <source>Nat. Immunol.</source>
<volume>15</volume>:<fpage>790</fpage>â<lpage>797</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2959</pub-id><pub-id pub-id-type="pmid">25137453</pub-id></mixed-citation>
      </ref>
      <ref id="bib23">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangan</surname><given-names>B.A.</given-names></name>, <name name-style="western"><surname>Dunne</surname><given-names>M.R.</given-names></name>, <name name-style="western"><surname>OâReilly</surname><given-names>V.P.</given-names></name>, <name name-style="western"><surname>Dunne</surname><given-names>P.J.</given-names></name>, <name name-style="western"><surname>Exley</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>OâShea</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Scotet</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Hogan</surname><given-names>A.E.</given-names></name>, and <name name-style="western"><surname>Doherty</surname><given-names>D.G.</given-names></name></person-group>
<year>2013</year>
<article-title>Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human VÎ´3 T cells</article-title>. <source>J. Immunol.</source>
<volume>191</volume>:<fpage>30</fpage>â<lpage>34</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1300121</pub-id><pub-id pub-id-type="pmid">23740951</pub-id></mixed-citation>
      </ref>
      <ref id="bib24">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marie-Cardine</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kirchgessner</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Bruyns</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Shevchenko</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mann</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Autschbach</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Ratnofsky</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Meuer</surname><given-names>S.</given-names></name>, and <name name-style="western"><surname>Schraven</surname><given-names>B.</given-names></name></person-group>
<year>1999</year>
<article-title>SHP2-interacting transmembrane adaptor protein (SIT), a novel disulfide-linked dimer regulating human T cell activation</article-title>. <source>J. Exp. Med.</source>
<volume>189</volume>:<fpage>1181</fpage>â<lpage>1194</lpage>. <pub-id pub-id-type="doi">10.1084/jem.189.8.1181</pub-id><pub-id pub-id-type="pmid">10209036</pub-id></mixed-citation>
      </ref>
      <ref id="bib25">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>May</surname><given-names>R.M.</given-names></name>, <name name-style="western"><surname>Okumura</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>C.J.</given-names></name>, <name name-style="western"><surname>Bassiri</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Rak</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Mace</surname><given-names>E.M.</given-names></name>, <name name-style="western"><surname>Philip</surname><given-names>N.H.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Baumgart</surname><given-names>T.</given-names></name>, <etal/></person-group>
<year>2013</year>
<article-title>Murine natural killer immunoreceptors use distinct proximal signaling complexes to direct cell function</article-title>. <source>Blood.</source>
<volume>121</volume>:<fpage>3135</fpage>â<lpage>3146</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-12-474361</pub-id><pub-id pub-id-type="pmid">23407547</pub-id></mixed-citation>
      </ref>
      <ref id="bib26">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minegishi</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Rohrer</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Coustan-Smith</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Lederman</surname><given-names>H.M.</given-names></name>, <name name-style="western"><surname>Pappu</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Campana</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>A.C.</given-names></name>, and <name name-style="western"><surname>Conley</surname><given-names>M.E.</given-names></name></person-group>
<year>1999</year>
<article-title>An essential role for BLNK in human B cell development</article-title>. <source>Science.</source>
<volume>286</volume>:<fpage>1954</fpage>â<lpage>1957</lpage>. <pub-id pub-id-type="doi">10.1126/science.286.5446.1954</pub-id><pub-id pub-id-type="pmid">10583958</pub-id></mixed-citation>
      </ref>
      <ref id="bib27">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>NuÃ±ez-Cruz</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Aguado</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Richelme</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chetaille</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Mura</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Richelme</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pouyet</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Jouvin-Marche</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Xerri</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name>, and <name name-style="western"><surname>Malissen</surname><given-names>M.</given-names></name></person-group>
<year>2003</year>
<article-title>LAT regulates Î³Î´ T cell homeostasis and differentiation</article-title>. <source>Nat. Immunol.</source>
<volume>4</volume>:<fpage>999</fpage>â<lpage>1008</lpage>. <pub-id pub-id-type="doi">10.1038/ni977</pub-id><pub-id pub-id-type="pmid">12970761</pub-id></mixed-citation>
      </ref>
      <ref id="bib28">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kondo</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Matsuki</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Takata</surname><given-names>H.</given-names></name>, and <name name-style="western"><surname>Takiguchi</surname><given-names>M.</given-names></name></person-group>
<year>2008</year>
<article-title>Phenotypic classification of human CD<sub>4</sub><sup>+</sup> T cell subsets and their differentiation</article-title>. <source>Int. Immunol.</source>
<volume>20</volume>:<fpage>1189</fpage>â<lpage>1199</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxn075</pub-id><pub-id pub-id-type="pmid">18635582</pub-id></mixed-citation>
      </ref>
      <ref id="bib29">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou-Yang</surname><given-names>C.W.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Fuller</surname><given-names>D.M.</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Chuck</surname><given-names>M.I.</given-names></name>, <name name-style="western"><surname>Ogden</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q.J.</given-names></name>, and <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group>
<year>2012</year>
<article-title>Role of LAT in the granule-mediated cytotoxicity of CD8 T cells</article-title>. <source>Mol. Cell. Biol.</source>
<volume>32</volume>:<fpage>2674</fpage>â<lpage>2684</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00356-12</pub-id><pub-id pub-id-type="pmid">22566687</pub-id></mixed-citation>
      </ref>
      <ref id="bib30">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name>, and <name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name></person-group>
<year>2014</year>
<article-title>Low level of LAT-PLC-Î³1 interaction is associated with Th2 polarized differentiation: a contributing factor to the etiology of asthma</article-title>. <source>Cell. Immunol.</source>
<volume>290</volume>:<fpage>131</fpage>â<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellimm.2014.05.012</pub-id><pub-id pub-id-type="pmid">24978613</pub-id></mixed-citation>
      </ref>
      <ref id="bib31">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poltorak</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Meinert</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Stone</surname><given-names>J.C.</given-names></name>, <name name-style="western"><surname>Schraven</surname><given-names>B.</given-names></name>, and <name name-style="western"><surname>Simeoni</surname><given-names>L.</given-names></name></person-group>
<year>2014</year>
<article-title>Sos1 regulates sustained TCR-mediated Erk activation</article-title>. <source>Eur. J. Immunol.</source>
<volume>44</volume>:<fpage>1535</fpage>â<lpage>1540</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201344046</pub-id><pub-id pub-id-type="pmid">24497027</pub-id></mixed-citation>
      </ref>
      <ref id="bib32">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roifman</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Dadi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Somech</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Nahum</surname><given-names>A.</given-names></name>, and <name name-style="western"><surname>Sharfe</surname><given-names>N.</given-names></name></person-group>
<year>2010</year>
<article-title>Characterization of Î¶-associated protein, 70 kd (ZAP70)-deficient human lymphocytes</article-title>. <source>J. Allergy Clin. Immunol.</source>
<volume>126</volume>:<fpage>1226</fpage>â<lpage>33.e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2010.07.029</pub-id><pub-id pub-id-type="pmid">20864151</pub-id></mixed-citation>
      </ref>
      <ref id="bib33">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roncagalli</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Mingueneau</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>GrÃ©goire</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Malissen</surname><given-names>M.</given-names></name>, and <name name-style="western"><surname>Malissen</surname><given-names>B.</given-names></name></person-group>
<year>2010</year>
<article-title>LAT signaling pathology: an âautoimmuneâ condition without T cell self-reactivity</article-title>. <source>Trends Immunol.</source>
<volume>31</volume>:<fpage>253</fpage>â<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2010.05.001</pub-id><pub-id pub-id-type="pmid">20542732</pub-id></mixed-citation>
      </ref>
      <ref id="bib34">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roncagalli</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Hauri</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Fiore</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Sansoni</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kanduri</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Joly</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Malzac</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>LÃ¤hdesmÃ¤ki</surname><given-names>H.</given-names></name>, <etal/></person-group>
<year>2014</year>
<article-title>Quantitative proteomics analysis of signalosome dynamics in primary T cells identifies the surface receptor CD6 as a Lat adaptor-independent TCR signaling hub</article-title>. <source>Nat. Immunol.</source>
<volume>15</volume>:<fpage>384</fpage>â<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2843</pub-id><pub-id pub-id-type="pmid">24584089</pub-id></mixed-citation>
      </ref>
      <ref id="bib35">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakaguchi</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Takahashi</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hata</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Nomura</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Tagami</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Yamazaki</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sakihama</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Matsutani</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Negishi</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Nakatsuru</surname><given-names>S.</given-names></name>, and <name name-style="western"><surname>Sakaguchi</surname><given-names>S.</given-names></name></person-group>
<year>2003</year>
<article-title>Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice</article-title>. <source>Nature.</source>
<volume>426</volume>:<fpage>454</fpage>â<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1038/nature02119</pub-id><pub-id pub-id-type="pmid">14647385</pub-id></mixed-citation>
      </ref>
      <ref id="bib36">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>SchatorjÃ©</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Gemen</surname><given-names>E.F.</given-names></name>, <name name-style="western"><surname>Driessen</surname><given-names>G.J.</given-names></name>, <name name-style="western"><surname>Leuvenink</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>van Hout</surname><given-names>R.W.</given-names></name>, and <name name-style="western"><surname>de Vries</surname><given-names>E.</given-names></name></person-group>
<year>2012</year>
<article-title>Paediatric reference values for the peripheral T cell compartment</article-title>. <source>Scand. J. Immunol.</source>
<volume>75</volume>:<fpage>436</fpage>â<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3083.2012.02671.x</pub-id><pub-id pub-id-type="pmid">22420532</pub-id></mixed-citation>
      </ref>
      <ref id="bib37">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shan</surname><given-names>X.</given-names></name>, and <name name-style="western"><surname>Wange</surname><given-names>R.L.</given-names></name></person-group>
<year>1999</year>
<article-title>Itk/Emt/Tsk activation in response to CD3 cross-linking in Jurkat T cells requires ZAP-70 and Lat and is independent of membrane recruitment</article-title>. <source>J. Biol. Chem.</source>
<volume>274</volume>:<fpage>29323</fpage>â<lpage>29330</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.41.29323</pub-id><pub-id pub-id-type="pmid">10506192</pub-id></mixed-citation>
      </ref>
      <ref id="bib38">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siggs</surname><given-names>O.M.</given-names></name>, <name name-style="western"><surname>Miosge</surname><given-names>L.A.</given-names></name>, <name name-style="western"><surname>Yates</surname><given-names>A.L.</given-names></name>, <name name-style="western"><surname>Kucharska</surname><given-names>E.M.</given-names></name>, <name name-style="western"><surname>Sheahan</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Brdicka</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Liston</surname><given-names>A.</given-names></name>, and <name name-style="western"><surname>Goodnow</surname><given-names>C.C.</given-names></name></person-group>
<year>2007</year>
<article-title>Opposing functions of the T cell receptor kinase ZAP-70 in immunity and tolerance differentially titrate in response to nucleotide substitutions</article-title>. <source>Immunity.</source>
<volume>27</volume>:<fpage>912</fpage>â<lpage>926</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2007.11.013</pub-id><pub-id pub-id-type="pmid">18093540</pub-id></mixed-citation>
      </ref>
      <ref id="bib39">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith-Garvin</surname><given-names>J.E.</given-names></name>, <name name-style="western"><surname>Koretzky</surname><given-names>G.A.</given-names></name>, and <name name-style="western"><surname>Jordan</surname><given-names>M.S.</given-names></name></person-group>
<year>2009</year>
<article-title>T cell activation</article-title>. <source>Annu. Rev. Immunol.</source>
<volume>27</volume>:<fpage>591</fpage>â<lpage>619</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132706</pub-id><pub-id pub-id-type="pmid">19132916</pub-id></mixed-citation>
      </ref>
      <ref id="bib40">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sommers</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Menon</surname><given-names>R.K.</given-names></name>, <name name-style="western"><surname>Grinberg</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Samelson</surname><given-names>L.E.</given-names></name>, and <name name-style="western"><surname>Love</surname><given-names>P.E.</given-names></name></person-group>
<year>2001</year>
<article-title>Knock-in mutation of the distal four tyrosines of linker for activation of T cells blocks murine T cell development</article-title>. <source>J. Exp. Med.</source>
<volume>194</volume>:<fpage>135</fpage>â<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1084/jem.194.2.135</pub-id><pub-id pub-id-type="pmid">11457888</pub-id></mixed-citation>
      </ref>
      <ref id="bib41">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sommers</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>C.S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Fuller</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Grinberg</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hildebrand</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>LacanÃ¡</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Menon</surname><given-names>R.K.</given-names></name>, <name name-style="western"><surname>Shores</surname><given-names>E.W.</given-names></name>, <etal/></person-group>
<year>2002</year>
<article-title>A LAT mutation that inhibits T cell development yet induces lymphoproliferation</article-title>. <source>Science.</source>
<volume>296</volume>:<fpage>2040</fpage>â<lpage>2043</lpage>. <pub-id pub-id-type="doi">10.1126/science.1069066</pub-id><pub-id pub-id-type="pmid">12065840</pub-id></mixed-citation>
      </ref>
      <ref id="bib42">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sommers</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Steiner</surname><given-names>K.L.</given-names></name>, <name name-style="western"><surname>Gurson</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Depersis</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>El-Khoury</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Fuller</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Shores</surname><given-names>E.W.</given-names></name>, <name name-style="western"><surname>Love</surname><given-names>P.E.</given-names></name>, and <name name-style="western"><surname>Samelson</surname><given-names>L.E.</given-names></name></person-group>
<year>2005</year>
<article-title>Mutation of the phospholipase C-Î³1-binding site of LAT affects both positive and negative thymocyte selection</article-title>. <source>J. Exp. Med.</source>
<volume>201</volume>:<fpage>1125</fpage>â<lpage>1134</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20041869</pub-id><pub-id pub-id-type="pmid">15795236</pub-id></mixed-citation>
      </ref>
      <ref id="bib43">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stepanek</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Draber</surname><given-names>P.</given-names></name>, and <name name-style="western"><surname>Horejsi</surname><given-names>V.</given-names></name></person-group>
<year>2014</year>
<article-title>Palmitoylated transmembrane adaptor proteins in leukocyte signaling</article-title>. <source>Cell. Signal.</source>
<volume>26</volume>:<fpage>895</fpage>â<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2014.01.007</pub-id><pub-id pub-id-type="pmid">24440308</pub-id></mixed-citation>
      </ref>
      <ref id="bib44">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stepensky</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Saada</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Cowan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Tabib</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Berkun</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Saleh</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Simanovsky</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kogot-Levin</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Weintraub</surname><given-names>M.</given-names></name>, <etal/></person-group>
<year>2013</year>
<article-title>The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy</article-title>. <source>Blood.</source>
<volume>121</volume>:<fpage>5078</fpage>â<lpage>5087</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-12-475566</pub-id><pub-id pub-id-type="pmid">23599270</pub-id></mixed-citation>
      </ref>
      <ref id="bib45">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Gent</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>van Tilburg</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Nibbelke</surname><given-names>E.E.</given-names></name>, <name name-style="western"><surname>Otto</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Gaiser</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Janssens-Korpela</surname><given-names>P.L.</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>E.A.</given-names></name>, <name name-style="western"><surname>Borghans</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Wulffraat</surname><given-names>N.M.</given-names></name>, <name name-style="western"><surname>Bierings</surname><given-names>M.B.</given-names></name>, <etal/></person-group>
<year>2009</year>
<article-title>Refined characterization and reference values of the pediatric T- and B-cell compartments</article-title>. <source>Clin. Immunol.</source>
<volume>133</volume>:<fpage>95</fpage>â<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2009.05.020</pub-id><pub-id pub-id-type="pmid">19586803</pub-id></mixed-citation>
      </ref>
      <ref id="bib46">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villa</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Notarangelo</surname><given-names>L.D.</given-names></name>, and <name name-style="western"><surname>Roifman</surname><given-names>C.M.</given-names></name></person-group>
<year>2008</year>
<article-title>Omenn syndrome: inflammation in leaky severe combined immunodeficiency</article-title>. <source>J. Allergy Clin. Immunol.</source>
<volume>122</volume>:<fpage>1082</fpage>â<lpage>1086</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2008.09.037</pub-id><pub-id pub-id-type="pmid">18992930</pub-id></mixed-citation>
      </ref>
      <ref id="bib47">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>N.</given-names></name>, and <name name-style="western"><surname>Raulet</surname><given-names>D.H.</given-names></name></person-group>
<year>2007</year>
<article-title>Development and selection of Î³Î´ T cells</article-title>. <source>Immunol. Rev.</source>
<volume>215</volume>:<fpage>15</fpage>â<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-065X.2006.00478.x</pub-id><pub-id pub-id-type="pmid">17291276</pub-id></mixed-citation>
      </ref>
      <ref id="bib48">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Irvin</surname><given-names>B.J.</given-names></name>, <name name-style="western"><surname>Trible</surname><given-names>R.P.</given-names></name>, <name name-style="western"><surname>Abraham</surname><given-names>R.T.</given-names></name>, and <name name-style="western"><surname>Samelson</surname><given-names>L.E.</given-names></name></person-group>
<year>1999</year><comment>a</comment>
<article-title>Functional analysis of LAT in TCR-mediated signaling pathways using a LAT-deficient Jurkat cell line</article-title>. <source>Int. Immunol.</source>
<volume>11</volume>:<fpage>943</fpage>â<lpage>950</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/11.6.943</pub-id><pub-id pub-id-type="pmid">10360968</pub-id></mixed-citation>
      </ref>
      <ref id="bib49">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Sommers</surname><given-names>C.L.</given-names></name>, <name name-style="western"><surname>Burshtyn</surname><given-names>D.N.</given-names></name>, <name name-style="western"><surname>Stebbins</surname><given-names>C.C.</given-names></name>, <name name-style="western"><surname>DeJarnette</surname><given-names>J.B.</given-names></name>, <name name-style="western"><surname>Trible</surname><given-names>R.P.</given-names></name>, <name name-style="western"><surname>Grinberg</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Tsay</surname><given-names>H.C.</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>H.M.</given-names></name>, <name name-style="western"><surname>Kessler</surname><given-names>C.M.</given-names></name>, <etal/></person-group>
<year>1999</year><comment>b</comment>
<article-title>Essential role of LAT in T cell development</article-title>. <source>Immunity.</source>
<volume>10</volume>:<fpage>323</fpage>â<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(00)80032-1</pub-id><pub-id pub-id-type="pmid">10204488</pub-id></mixed-citation>
      </ref>
      <ref id="bib50">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Trible</surname><given-names>R.P.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S.K.</given-names></name>, <name name-style="western"><surname>McGlade</surname><given-names>C.J.</given-names></name>, and <name name-style="western"><surname>Samelson</surname><given-names>L.E.</given-names></name></person-group>
<year>2000</year>
<article-title>Association of Grb2, Gads, and phospholipase C-Î³1 with phosphorylated LAT tyrosine residues. Effect of LAT tyrosine mutations on T cell angigen receptor-mediated signaling</article-title>. <source>J. Biol. Chem.</source>
<volume>275</volume>:<fpage>23355</fpage>â<lpage>23361</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M000404200</pub-id><pub-id pub-id-type="pmid">10811803</pub-id></mixed-citation>
      </ref>
      <ref id="bib51">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Janssen</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>K.</given-names></name>, and <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group>
<year>2002</year>
<article-title>Molecular cloning of a novel gene encoding a membrane-associated adaptor protein (LAX) in lymphocyte signaling</article-title>. <source>J. Biol. Chem.</source>
<volume>277</volume>:<fpage>46151</fpage>â<lpage>46158</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M208946200</pub-id><pub-id pub-id-type="pmid">12359715</pub-id></mixed-citation>
      </ref>
      <ref id="bib52">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Koonpaew</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Denning</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Dzhagalov</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Rhee</surname><given-names>I.</given-names></name>, and <name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group>
<year>2006</year>
<article-title>Negative regulation of T cell activation and autoimmunity by the transmembrane adaptor protein LAB</article-title>. <source>Immunity.</source>
<volume>25</volume>:<fpage>757</fpage>â<lpage>768</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2006.08.025</pub-id><pub-id pub-id-type="pmid">17081783</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>